Difference between revisions of "Team:NCKU Tainan/Results"

 
(27 intermediate revisions by 3 users not shown)
Line 25: Line 25:
 
                 </ul>
 
                 </ul>
 
             </aside>
 
             </aside>
             <main class="">
+
             <main class="">        
 
                 <!--The Page Name-->     
 
                 <!--The Page Name-->     
 
                 <br></br>
 
                 <br></br>
Line 35: Line 35:
 
                     <h2 id ="Subtitle1">Menbles Production Experiments</h2>
 
                     <h2 id ="Subtitle1">Menbles Production Experiments</h2>
 
                     <h3>Goal</h3>
 
                     <h3>Goal</h3>
                     <p>&emsp;&emsp;To test whether our final product (Menbles) can effectively protect <i>E. coli</i> Nissle 1917 inside the bubble under the pH conditions of the milk tea, and to compare which bubble size has the best efficiency in protecting our bacteria.</p>
+
                     <p>&emsp;&emsp;To test whether Menbles final product can effectively protect <i>E. coli</i> Nissle 1917 under different pH values of milk tea, and to compare which bubble size is the most capable to protect our bacteria.</p>
 
                     <h3>Achievements</h3>
 
                     <h3>Achievements</h3>
                     <p>1. Proved that the bubble is effective to protect the bacteria inside, maximize recovery, and minimize losing the bacteria before being digested, in the pH conditions of the milk tea.</p>
+
                     <p>1. Proved that the bubble is effective to protect the bacteria inside by minimizing loss of bacteria, in the pH conditions of milk tea.</p>
                   <p>2. Identified which bubble size is the most stable based on recovery rates.</p>
+
                   <p>2. Identified which bubble size has the best structure based on recovery rates.</p>
 
                     <h3>Process</h3>
 
                     <h3>Process</h3>
                     <p>&emsp;&emsp;After deciding the raw materials used for our bubble, which are sodium alginate and calcium chloride, we immediately conducted experiments testing the amount of bacteria recovered from the bubble itself at different pHs of the milk tea. We tested with 4 different pHs, pH 4.5, 5.0, 5.5, and 7.0. The bubble is produced by mixing 2 ml of 1 OD<sub>600</sub> <i>E. coli</i> Nissle 1917 with 50 ml alginate solution, and 2.5 ml of the solution is dripped drop by drop using different volumes of laboratory pipettes into a calcium chloride solution. As a result, we experimented with 3 different sizes of the bubble, with volumes approximately 14.14 mm<sup>3</sup> (Large), 4.19 mm<sup>3</sup> (Medium), and 1.77 mm<sup>3</sup> (Small). </p>
+
                     <p>&emsp;&emsp;After we decided on sodium alginate and calcium chloride as the raw material for Menbles, we conducted several experiments to test the number of bacteria recovered from the bubble at different pH levels of milk tea (4.5, 5.0, 5.5, 7.0). Menbles is produced by mixing 2 ml of freshly cultured <i>E. coli</i> Nissle 1917 (OD<sub>600</sub> = 1) with 50 ml of alginate solution, then using different sizes of laboratory pipettes we dripped 2.5 ml of the solution drop by drop into calcium chloride solution. As the result of different pipette sizes being used, there are three different sizes of the bubble, with the volumes approximately equal to 14.14 mm<sup>3</sup> (Large), 4.19 mm<sup>3</sup> (Medium), and 1.77 mm<sup>3</sup> (Small).</p>
 
                       <div class="container-fluid p-0">
 
                       <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 51: Line 51:
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                     <p>&emsp;&emsp;The bubbles are then separated from the calcium chloride solution using filtration, and  the bubbles are equally distributed and submerged into 12.5 ml disodium hydrogen diphosphate buffer of the 4 different pHs for 2 hours in room temperature.</p>
+
<div class="container-fluid p-0">
           <p>&emsp;&emsp;After 2 hours, 60 μl of the supernatant for every pH is spread onto an LB plate medium, used as the supernatant data. Then, the bubbles are separated from the buffer and crushed using a syringe, in which after crushing, the crushed bubbles are then put back into the buffer separated earlier. 60 μl of the supernatant is again spread onto another LB plate medium, which will then be used as the bubble data. A negative control experiment involving just the buffer of different pHs without bubbles submerged in it is also spread onto another LB plate medium, to identify any contamination that could affect the result of the experiment.</p>
+
                        <div class="row no-gutters">
                     <p>&emsp;&emsp;The plates are then incubated for 12 hours in 37°C, in which after incubation CFU quantification is conducted to determine the bacteria recovery rate of the bubble. The results below are the bacteria recovery rate of the 14.14 mm<sup>3</sup> (Large) bubble, 4.19 mm<sup>3</sup> (Medium) bubble, and 1.77 mm<sup>3</sup> (Small) bubble (Fig. 2). All our negative control plates did not grow any colonies, so the results obtained are devoid of any contamination. To count the percentage of bacteria, we multiplied the CFU number we obtained from the plate, with the dilution of the sample (60 μl/15 ml) and divided by the total number of bacteria that is supposed to be inside. By calculating the amount of bacteria that is supposed to be in the bubbles in each pH buffer, we can approximately calculate the percentage of bacteria in the supernatant after 2 hours, and the amount of bacteria recovered after crushing the bubble. </p>
+
                            <div class="col-lg ">
 +
                                <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 +
                                    <a href="https://static.igem.org/mediawiki/2021/4/45/T--NCKU_Tainan--menblesexperimentprocedure.jpeg" target="_blank" style="width:100%"><img src="https://static.igem.org/mediawiki/2021/4/45/T--NCKU_Tainan--menblesexperimentprocedure.jpeg" alt="" title=""style="width:100%;"></a>
 +
                                  <figcaption class="mt-3">Fig. 2. Menbles Experiment Procedure</figcaption>
 +
                                </figure>
 +
                            </div>
 +
                        </div>
 +
                    </div>
 +
                     <p>&emsp;&emsp;Then, the bubbles were extracted from calcium chloride solution through filtration, which would be equally distributed and submerged into 12.5 ml of disodium hydrogen diphosphate buffer with 4 different pH levels for 2 hours at room temperature.</p>
 +
           <p>&emsp;&emsp;After the bubbles were submerged for 2 hours, 60 μl of supernatant from every pH sample was smeared culture into LB plate medium, and the rest of the bubbles were separated from the buffer than would be crushed with the compression of a syringe. The crushed bubble should be submerged back into its original buffer, then 60 μl of supernatant samples were smeared again to another LB medium. Negative controls were also smeared into LB medium which involves buffer without any bubble present to identify any possible contamination.</p>
 +
                     <p>&emsp;&emsp;After the plates were incubated for 12 hours at 37°C, CFU quantification was conducted to determine the bacteria recovery rate from the bubble. By calculating the amount of bacteria supposed to be inside the bubble in each pH buffer, we can approximate the percentage of bacteria recovered both in the supernatant and the crushed bubble. The results shown in Fig. 3. are the bacteria recovery rate of the large, medium, and small bubbles, with additional negative control plates did not grow any colonies, so the results obtained are devoid of any contamination.</p>
 
                       <div class="container-fluid p-0">
 
                       <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 59: Line 69:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/3/3f/T--NCKU_Tainan--menbleresultcombined.png" target="_blank" style="width:100%"><img src="https://static.igem.org/mediawiki/2021/3/3f/T--NCKU_Tainan--menbleresultcombined.png" alt="" title=""style="width:100%;"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/3/3f/T--NCKU_Tainan--menbleresultcombined.png" target="_blank" style="width:100%"><img src="https://static.igem.org/mediawiki/2021/3/3f/T--NCKU_Tainan--menbleresultcombined.png" alt="" title=""style="width:100%;"></a>
                                     <figcaption class="mt-3">Fig. 2. The recovery percentage of <i>E. coli</i> Nissle 1917 in bubbles with volume 14.14 mm³ (Large), 4.19 mm³ (Medium), and 1.77 mm³ (Small).</figcaption>
+
                                     <figcaption class="mt-3">Fig. 3. The recovery percentage of <i>E. coli</i> Nissle 1917 in bubbles with volume 14.14 mm³ (Large), 4.19 mm³ (Medium), and 1.77 mm³ (Small).</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
 +
                  <p>&emsp;&emsp;Based on the results shown in Fig. 3, we concluded that the bubble with a volume of 4.19 mm<sup>3</sup> (Medium) delivers the best results due to its stable recovery rate and suits our hypothesis of a lower pH will lower down the bacteria loss.</p>
 
           </section>
 
           </section>
 
                 <hr>
 
                 <hr>
Line 77: Line 88:
 
                   <h5>Process</h5>
 
                   <h5>Process</h5>
 
                   <p>&emsp;&emsp;<b> In <i>E. coli</i>, there are two main promoters that can detect oxidative stress, the <i>katG</i> promoter (<i>P<sub>katG</sub></i>) (<a href="http://parts.igem.org/Part:BBa_K3771047" target="_blank">BBa_K3771047</a>) and the <i>soxS</i> promoter (<i>P<sub>soxS</sub></i>) (<a href="http://parts.igem.org/Part:BBa_K3771048" target="_blank">BBa_K3771048</a>)</b>. To determine which promoter to use in our final biobrick in order to express the taurine-producing enzyme, an oxidative stress assay is essential. Hence, we need to construct plasmids with different promoters and utilize the reporter, sfGFP, to determine the intensity and sensitivity of both promoters.</p>
 
                   <p>&emsp;&emsp;<b> In <i>E. coli</i>, there are two main promoters that can detect oxidative stress, the <i>katG</i> promoter (<i>P<sub>katG</sub></i>) (<a href="http://parts.igem.org/Part:BBa_K3771047" target="_blank">BBa_K3771047</a>) and the <i>soxS</i> promoter (<i>P<sub>soxS</sub></i>) (<a href="http://parts.igem.org/Part:BBa_K3771048" target="_blank">BBa_K3771048</a>)</b>. To determine which promoter to use in our final biobrick in order to express the taurine-producing enzyme, an oxidative stress assay is essential. Hence, we need to construct plasmids with different promoters and utilize the reporter, sfGFP, to determine the intensity and sensitivity of both promoters.</p>
                   <p>&emsp;&emsp;First, we conducted PCR to amplify the fragment of <i>P<sub>katG</sub></i>, <i>P<sub>soxS</sub></i>, and <i>soxR</i> gene with <i>P<sub>soxS</sub></i> from the chromosome of <i>E. coli</i> MG1655. SoxR is a transcriptional activator of <i>P<sub>soxS</sub></i>. The fragments were used to replace J23100 promoter in pSAA-J23100-<i>sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771050" target="_blank">BBa_K3771050</a>). We obtained three new plasmids, pSAA-<i>P<sub>katG</sub>-sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771091" target="_blank">BBa_K3771091</a>), pSAA-<i>P<sub>soxS</sub>-sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771092" target="_blank">BBa_K3771092</a>), and pSAA-<i>soxR</i>-<i>P<sub>soxS</sub>-sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771093" target="_blank">BBa_K3771093</a>). To ensure the correctness of the sequence, we conducted colony PCR after transformation and the result showed that the plasmid contains the correct sequence (Fig. 3).</p>
+
                   <p>&emsp;&emsp;First, we conducted PCR to amplify the fragment of <i>P<sub>katG</sub></i>, <i>P<sub>soxS</sub></i>, and <i>soxR</i> gene with <i>P<sub>soxS</sub></i> from the chromosome of <i>E. coli</i> MG1655. SoxR is a transcriptional activator of <i>P<sub>soxS</sub></i>. The fragments were used to replace J23100 promoter in pSAA-J23100-<i>sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771050" target="_blank">BBa_K3771050</a>). We obtained three new plasmids, pSAA-<i>P<sub>katG</sub>-sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771091" target="_blank">BBa_K3771091</a>), pSAA-<i>P<sub>soxS</sub>-sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771092" target="_blank">BBa_K3771092</a>), and pSAA-<i>soxR</i>-<i>P<sub>soxS</sub>-sfgfp</i> (<a href="http://parts.igem.org/Part:BBa_K3771093" target="_blank">BBa_K3771093</a>). To ensure the correctness of the sequence, we conducted colony PCR after transformation and the result showed that the plasmid contains the correct sequence (Fig. 4).</p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 84: Line 95:
 
                                     <!-- put link in href & src , width in a can adjust-->
 
                                     <!-- put link in href & src , width in a can adjust-->
 
                                     <a href="https://static.igem.org/mediawiki/2021/1/15/T--NCKU_Tainan--PkatG%2C_PsoxS%2C_soxR-PsoxS_Colony_PCR.png" target="_blank" style="width:90%"><img src="https://static.igem.org/mediawiki/2021/1/15/T--NCKU_Tainan--PkatG%2C_PsoxS%2C_soxR-PsoxS_Colony_PCR.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/1/15/T--NCKU_Tainan--PkatG%2C_PsoxS%2C_soxR-PsoxS_Colony_PCR.png" target="_blank" style="width:90%"><img src="https://static.igem.org/mediawiki/2021/1/15/T--NCKU_Tainan--PkatG%2C_PsoxS%2C_soxR-PsoxS_Colony_PCR.png" alt="" title="" style="width:100%"></a>
                                     <figcaption>Fig. 3. The electrophoresis result of colony PCR of (A) pSAA-<i>P<sub>katG</sub>-sfgfp</i> (BBa_K3771091), (B) pSAA-<i>P<sub>soxS</sub>-sfgfp</i>, (BBa_K3771092), and (C) pSAA-<i>soxR</i>-<i>P<sub>soxS</sub>-sfgfp</i> (BBa_K3771093). (A) M: Marker; Lane 1, 2: pSAA-<i>P<sub>katG</sub>-sfgfp</i> (2629 bp); Lane 3: pSAA-J23100-<i>sfgfp</i> (2537 bp).​ (B) M: Marker; Lane 1: pSAA-J23100-<i>sfgfp</i> (2537 bp); Lane 2, 3: pSAA-<i>P<sub>soxS</sub>-sfgfp</i> (3122 bp). (C) M: Marker; Lane 1, 2: pSAA-<i>soxR</i>-<i>P<sub>soxS</sub>-sfgfp</i> (3327 bp); Lane 3: pSAA-<i>P<sub>soxS</sub>-sfgfp</i> (2691 bp).</figcaption>
+
                                     <figcaption>Fig. 4. The electrophoresis result of colony PCR of (A) pSAA-<i>P<sub>katG</sub>-sfgfp</i> (BBa_K3771091), (B) pSAA-<i>P<sub>soxS</sub>-sfgfp</i>, (BBa_K3771092), and (C) pSAA-<i>soxR</i>-<i>P<sub>soxS</sub>-sfgfp</i> (BBa_K3771093). (A) M: Marker; Lane 1, 2: pSAA-<i>P<sub>katG</sub>-sfgfp</i> (2629 bp); Lane 3: pSAA-J23100-<i>sfgfp</i> (2537 bp).​ (B) M: Marker; Lane 1: pSAA-J23100-<i>sfgfp</i> (2537 bp); Lane 2, 3: pSAA-<i>P<sub>soxS</sub>-sfgfp</i> (3122 bp). (C) M: Marker; Lane 1, 2: pSAA-<i>soxR</i>-<i>P<sub>soxS</sub>-sfgfp</i> (3327 bp); Lane 3: pSAA-<i>P<sub>soxS</sub>-sfgfp</i> (2691 bp).</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 95: Line 106:
 
                   <h5><b>Process</b></h5>
 
                   <h5><b>Process</b></h5>
 
                   <p>&emsp;&emsp;We compared the relative fluorescence intensity of sfGFP expressed by different promoters when induced by different concentrations of paraquat (PQ). Paraquat can react with oxygen to produce various types of reactive oxygen species (ROS), such as superoxide radical (O<sub>2</sub><sup>−</sup>•), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and hydroxyl radical (OH<sup>−</sup>•)<sup>[<a href="#ref5">5</a>]</sup>, which is used to simulate abnormal oxidative stress in the intestines of stressed individuals. </p>
 
                   <p>&emsp;&emsp;We compared the relative fluorescence intensity of sfGFP expressed by different promoters when induced by different concentrations of paraquat (PQ). Paraquat can react with oxygen to produce various types of reactive oxygen species (ROS), such as superoxide radical (O<sub>2</sub><sup>−</sup>•), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and hydroxyl radical (OH<sup>−</sup>•)<sup>[<a href="#ref5">5</a>]</sup>, which is used to simulate abnormal oxidative stress in the intestines of stressed individuals. </p>
         <p>&emsp;&emsp;Over a period of 4.5 hours after paraquat was added, the relative fluorescence intensity was measured. J23100, a constitutive promoter, being the positive control, shows no difference in sfGFP expression level between the samples with and without paraquat. The activity of <i>P<sub>soxS</sub></i> (<a href="http://parts.igem.org/Part:BBa_K3771048" target="_blank">BBa_K3771048</a>) is higher than that of <i>P<sub>katG</sub></i> (<a href="http://parts.igem.org/Part:BBa_K3771047" target="_blank">BBa_K3771047</a>), but the activity is greatest when the SoxR transcription factor (<a href="http://parts.igem.org/Part:BBa_K3771100" target="_blank">BBa_K3771100</a>) is added in the construction together with <i>P<sub>soxS</sub></i> (Fig. 4 and 5).</p>
+
         <p>&emsp;&emsp;Over a period of 4.5 hours after paraquat was added, the relative fluorescence intensity was measured. J23100, a constitutive promoter, being the positive control, shows no difference in sfGFP expression level between the samples with and without paraquat. The activity of <i>P<sub>soxS</sub></i> (<a href="http://parts.igem.org/Part:BBa_K3771048" target="_blank">BBa_K3771048</a>) is higher than that of <i>P<sub>katG</sub></i> (<a href="http://parts.igem.org/Part:BBa_K3771047" target="_blank">BBa_K3771047</a>), but the activity is greatest when the SoxR transcription factor (<a href="http://parts.igem.org/Part:BBa_K3771100" target="_blank">BBa_K3771100</a>) is added in the construction together with <i>P<sub>soxS</sub></i> (Fig. 5 and 6).</p>
 
           <div class="container-fluid p-0" >
 
           <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 101: Line 112:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/parts/c/c2/T--NCKU_Tainan--sfGFP_Expression_%28PQ_%404.5h%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/c/c2/T--NCKU_Tainan--sfGFP_Expression_%28PQ_%404.5h%29.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/parts/c/c2/T--NCKU_Tainan--sfGFP_Expression_%28PQ_%404.5h%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/c/c2/T--NCKU_Tainan--sfGFP_Expression_%28PQ_%404.5h%29.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 4. sfGFP expression under high concentration of PQ</figcaption>
+
                                     <figcaption class="mt-3">Fig. 5. sfGFP expression under high concentration of PQ</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 107: Line 118:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/parts/0/0d/T--NCKU_Tainan--Low_sfGFP_Expression_%28PQ_%404.5h%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/0/0d/T--NCKU_Tainan--Low_sfGFP_Expression_%28PQ_%404.5h%29.png" alt="" title="" style="width:110%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/parts/0/0d/T--NCKU_Tainan--Low_sfGFP_Expression_%28PQ_%404.5h%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/0/0d/T--NCKU_Tainan--Low_sfGFP_Expression_%28PQ_%404.5h%29.png" alt="" title="" style="width:110%"></a>
                                     <figcaption class="mt-3">Fig. 5. sfGFP expression under lower concentration of PQ. The comparison of different promoter strengths by relative fluorescence intensity after 4.5-hour incubation with paraquat in various concentrations was shown in these two  pictures.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 6. sfGFP expression under lower concentration of PQ. The comparison of different promoter strengths by relative fluorescence intensity after 4.5-hour incubation with paraquat in various concentrations was shown in these two  pictures.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>&emsp;&emsp;Another oxidative stress assay was performed only with SoxR and <i>P<sub>soxS</sub></i> promoter to determine the efficiency of this detection system. The sfGFP level was measured hourly during the 4.5 hours after paraquat induction, and results showed that even low concentrations of paraquat were able to activate the detection system (Fig. 6 and 7).</p>
+
                   <p>&emsp;&emsp;Another oxidative stress assay was performed only with SoxR and <i>P<sub>soxS</sub></i> promoter to determine the efficiency of this detection system. The sfGFP level was measured hourly during the 4.5 hours after paraquat induction, and results showed that even low concentrations of paraquat were able to activate the detection system (Fig. 7 and 8).</p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 118: Line 129:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/parts/3/33/T--NCKU_Tainan--Del_Low_sfGFP_Expression_%28soxR-PsoxS%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/3/33/T--NCKU_Tainan--Del_Low_sfGFP_Expression_%28soxR-PsoxS%29.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/parts/3/33/T--NCKU_Tainan--Del_Low_sfGFP_Expression_%28soxR-PsoxS%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/3/33/T--NCKU_Tainan--Del_Low_sfGFP_Expression_%28soxR-PsoxS%29.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 6. sfGFP expression under low concentration of PQ.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 7. sfGFP expression under low concentration of PQ.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 124: Line 135:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/parts/0/0c/T--NCKU_Tainan--Del_High_sfGFP_Expression_%28soxR-PsoxS%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/0/0c/T--NCKU_Tainan--Del_High_sfGFP_Expression_%28soxR-PsoxS%29.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/parts/0/0c/T--NCKU_Tainan--Del_High_sfGFP_Expression_%28soxR-PsoxS%29.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/parts/0/0c/T--NCKU_Tainan--Del_High_sfGFP_Expression_%28soxR-PsoxS%29.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 7. sfGFP expression under high concentration of PQ. Relative fluorescence intensity of soxR-<i>P<sub>soxS</sub></i> after 4.5-hour incubation with paraquat in various concentrations was shown in these two  pictures.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 8. sfGFP expression under high concentration of PQ. Relative fluorescence intensity of soxR-<i>P<sub>soxS</sub></i> after 4.5-hour incubation with paraquat in various concentrations was shown in these two  pictures.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 133: Line 144:
 
                   <p>1. Construction of the plasmid containing the <i>soxRS</i> regulon and the <i>csad</i> gene.</p>
 
                   <p>1. Construction of the plasmid containing the <i>soxRS</i> regulon and the <i>csad</i> gene.</p>
 
                   <h4>Process</h4>
 
                   <h4>Process</h4>
                   <p>&emsp;&emsp;After confirming the function of <i>soxR</i>-P<i><sub>soxS</sub></i>, the coding sequence of sfGFP was replaced with the <i>csad gene</i>  (<a href="http://parts.igem.org/Part:BBa_K3771008" target="_blank">BBa_K3771008</a>), resulting in a new plasmid - pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-csad-6xHis</i> (<a href="http://parts.igem.org/Part:BBa_K3771097" target="_blank">BBa_K3771097</a>). This plasmid is essential for producing taurine in our project, and the 6xHis-tag was designed for detecting the expressed protein through western blot. We conducted colony PCR after transformation to verify whether <i>E. coli</i> uptook the correct plasmid. The size of the PCR product was as expected (Fig. 8). The plasmid was also confirmed by sequencing and has no mutations.</p>
+
                   <p>&emsp;&emsp;After confirming the function of <i>soxR</i>-P<i><sub>soxS</sub></i>, the coding sequence of sfGFP was replaced with the <i>csad gene</i>  (<a href="http://parts.igem.org/Part:BBa_K3771008" target="_blank">BBa_K3771008</a>), resulting in a new plasmid - pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-csad-6xHis</i> (<a href="http://parts.igem.org/Part:BBa_K3771097" target="_blank">BBa_K3771097</a>). This plasmid is essential for producing taurine in our project, and the 6xHis-tag was designed for detecting the expressed protein through western blot. We conducted colony PCR after transformation to verify whether <i>E. coli</i> uptook the correct plasmid. The size of the PCR product was as expected (Fig. 9). The plasmid was also confirmed by sequencing and has no mutations.</p>
 
                     <div class="container-fluid p-0">
 
                     <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 139: Line 150:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/0/03/T--NCKU_Tainan--soxR-CSAD_Colony_PCR.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/0/03/T--NCKU_Tainan--soxR-CSAD_Colony_PCR.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/0/03/T--NCKU_Tainan--soxR-CSAD_Colony_PCR.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/0/03/T--NCKU_Tainan--soxR-CSAD_Colony_PCR.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 8. The electrophoresis result of colony PCR of plasmid pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-csad-6xHis</i>. (BBa_K3771097) M: Marker; Lane 1: pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-sfgfp</i> (1050 bp);  Lane 2, 3: pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-csad-6xHis</i> (1829 bp).</figcaption>
+
                                     <figcaption class="mt-3">Fig. 9. The electrophoresis result of colony PCR of plasmid pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-csad-6xHis</i>. (BBa_K3771097) M: Marker; Lane 1: pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-sfgfp</i> (1050 bp);  Lane 2, 3: pSAA-<i>soxR</i>-P<i><sub>soxS</sub>-csad-6xHis</i> (1829 bp).</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 148: Line 159:
 
                   <p>1. Confirmation of CSAD (<a href="http://parts.igem.org/Part:BBa_K3771008" target="_blank">BBa_K3771008</a>) enzyme expression under oxidative stress by western blot.</p>
 
                   <p>1. Confirmation of CSAD (<a href="http://parts.igem.org/Part:BBa_K3771008" target="_blank">BBa_K3771008</a>) enzyme expression under oxidative stress by western blot.</p>
 
                   <h4>Process</h4>
 
                   <h4>Process</h4>
                   <p>&emsp;&emsp;To confirm that the CSAD enzyme is successfully expressed when induced by paraquat, the western blot was performed. When the OD<sub>600</sub> of the bacterial culture reached 0.5, we added 0.1 mM paraquat into the culture and collected samples at 2, 4, 6 hours after paraquat was added. The result confirmed that CSAD was expressed under oxidative stress. The sample collected at 6 hours after paraquat was added had the greatest expression, and CSAD expression increases as the time allowed for paraquat to induce the <i>SoxS</i> promoter increases (Fig. 9).</p>
+
                   <p>&emsp;&emsp;To confirm that the CSAD enzyme is successfully expressed when induced by paraquat, the western blot was performed. When the OD<sub>600</sub> of the bacterial culture reached 0.5, we added 0.1 mM paraquat into the culture and collected samples at 2, 4, 6 hours after paraquat was added. The result confirmed that CSAD was expressed under oxidative stress. The sample collected at 6 hours after paraquat was added had the greatest expression, and CSAD expression increases as the time allowed for paraquat to induce the <i>SoxS</i> promoter increases (Fig. 10).</p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 154: Line 165:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/5/58/T--NCKU_Tainan--soxR-CSAD_WB.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/5/58/T--NCKU_Tainan--soxR-CSAD_WB.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/5/58/T--NCKU_Tainan--soxR-CSAD_WB.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/5/58/T--NCKU_Tainan--soxR-CSAD_WB.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 9. The western blot result. CSAD (~55 kDa); –: control; PQ: 0.1 mM paraquat.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 10. The western blot result. CSAD (~55 kDa); –: control; PQ: 0.1 mM paraquat.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 178: Line 189:
 
                             <div class="col-lg">
 
                             <div class="col-lg">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/4/44/T--NCKU_Tainan--composite_pspA_OFP_pLacI_ompA_oprF.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/44/T--NCKU_Tainan--composite_pspA_OFP_pLacI_ompA_oprF.jpg" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/f/f8/T--NCKU_Tainan--pspAompA.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/f/f8/T--NCKU_Tainan--pspAompA.jpg" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 10. Confirmation of construction by PCR. (Left) M: Marker; Lane 1: <i>pspA</i> promoter (BBa_K3071013) (~218bp); Lane 2: <i>ompA/oprF</i> (BBa_K3771009) (~1110bp) </figcaption>
+
                                     <figcaption class="mt-3">Fig. 11. Confirmation of construction by PCR. (Left) M: Marker; Lane 1: <i>pspA</i> promoter (BBa_K3071013) (~218bp); Lane 2: <i>ompA/oprF</i> (BBa_K3771009) (~1110bp) </figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/2/20/T--NCKU_Tainan--composite_pspA_OFP_pOmpA_ompA_oprF.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/2/20/T--NCKU_Tainan--composite_pspA_OFP_pOmpA_ompA_oprF.jpg" alt="" title="" style="width:115%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/1/12/T--NCKU_Tainan--pspApompAompA.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/1/12/T--NCKU_Tainan--pspApompAompA.jpg" alt="" title="" style="width:115%"></a>
                                     <figcaption class="mt-3">Fig. 11. M: Marker; Lane 1: <i>pspA</i> promoter (~218bp); Lane 2: <i>ompA</i> promoter  (BBa_K3771011) (~309 bp); Lane 3: <i>ompA/oprF</i> (~1110bp)
+
                                     <figcaption class="mt-3">Fig. 12. M: Marker; Lane 1: <i>pspA</i> promoter (~218bp); Lane 2: <i>ompA</i> promoter  (BBa_K3771011) (~309 bp); Lane 3: <i>ompA/oprF</i> (~1110bp)
 
</figcaption>
 
</figcaption>
 
                                 </figure>
 
                                 </figure>
Line 197: Line 208:
 
             <p>3. Determined the time required for the system to produce a significant difference in protein expression</p>
 
             <p>3. Determined the time required for the system to produce a significant difference in protein expression</p>
 
           <h5><b>Process</b></h5>
 
           <h5><b>Process</b></h5>
                   <p>&emsp;&emsp;The two plasmids <i>P<sub>pspA</sub>-ofp</i>-<i>P<sub>lacI</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771017" target="_blank">BBa_K3771017</a>) and <i>P<sub>pspA</sub>-ofp</i>-<i>P<sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771018" target="_blank">BBa_K3771018</a>) were transformed into <i>ompA</i> gene knockout strain, JW0940, to prevent OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF. Human IFN-γ of concentrations 300 pM and 600 pM were added to bacteria cultures to induce the system. OFP expression (RFU) was recorded using a microplate reader and normalized by OD<sub>600</sub>. As shown in Fig. 12 and 13, starting at around 12 hours after induction, OFP expression of both samples increased dramatically. </p>
+
                   <p>&emsp;&emsp;The two plasmids <i>P<sub>pspA</sub>-ofp</i>-<i>P<sub>lacI</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771017" target="_blank">BBa_K3771017</a>) and <i>P<sub>pspA</sub>-ofp</i>-<i>P<sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771018" target="_blank">BBa_K3771018</a>) were transformed into <i>ompA</i> gene knockout strain, JW0940, to prevent OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF. Human IFN-γ of concentrations 300 pM and 600 pM were added to bacteria cultures to induce the system. OFP expression (RFU) was recorded using a microplate reader and normalized by OD<sub>600</sub>. As shown in Fig. 13 and 14, starting at around 12 hours after induction, OFP expression of both samples increased dramatically. </p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 203: Line 214:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/a/ab/T--NCKU_Tainan--proof_of_concept_4.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/a/ab/T--NCKU_Tainan--proof_of_concept_4.jpg" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/a/ab/T--NCKU_Tainan--proof_of_concept_4.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/a/ab/T--NCKU_Tainan--proof_of_concept_4.jpg" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 12. OFP expression of <i>P<sub>pspA</sub>-ofp-P<sub>lacI<sub>-ompA/oprF </i>(sample 1) (BBa_K3771017)  </figcaption>
+
                                     <figcaption class="mt-3">Fig. 13. OFP expression of <i>P<sub>pspA</sub>-ofp-P<sub>lacI<sub>-ompA/oprF </i>(sample 1) (BBa_K3771017)  </figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 209: Line 220:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--proof_of_concept_5.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--proof_of_concept_5.jpg" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--proof_of_concept_5.jpg" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--proof_of_concept_5.jpg" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 13. OFP expression of <i>P<sub>pspA</sub>-ofp-P<sub>ompA</sub>-ompA/oprF</i> (sample 2) (BBa_K3771018)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 14. OFP expression of <i>P<sub>pspA</sub>-ofp-P<sub>ompA</sub>-ompA/oprF</i> (sample 2) (BBa_K3771018)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>&emsp;&emsp;As presented in Fig. 14, at 12 hours after induction, sample 2 (<i>P<sub>pspA</sub>-ofp-P<sub>ompA</sub>-ompA/oprF</i>) (<a href="http://parts.igem.org/Part:BBa_K3771018" target="_blank">BBa_K3771018</a>) with the addition of 600 pM IFN-γ had higher OFP expression than that of sample 1 (<i>P<sub>pspA</sub>-ofp</i>-P<i><sub>lacI</sub>-ompA/oprF</i>) (<a href="http://parts.igem.org/Part:BBa_K3771017" target="_blank">BBa_K3771017</a>). Since <i>ompA</i> promoter stimulates higher protein expression than <i>lacI</i> promoter, we decided to incorporate the <i>ompA</i> promoter in our final biobrick to regulate the expression of CS. </p>
+
                   <p>&emsp;&emsp;As presented in Fig. 15, at 12 hours after induction, sample 2 (<i>P<sub>pspA</sub>-ofp-P<sub>ompA</sub>-ompA/oprF</i>) (<a href="http://parts.igem.org/Part:BBa_K3771018" target="_blank">BBa_K3771018</a>) with the addition of 600 pM IFN-γ had higher OFP expression than that of sample 1 (<i>P<sub>pspA</sub>-ofp</i>-P<i><sub>lacI</sub>-ompA/oprF</i>) (<a href="http://parts.igem.org/Part:BBa_K3771017" target="_blank">BBa_K3771017</a>). Since <i>ompA</i> promoter stimulates higher protein expression than <i>lacI</i> promoter, we decided to incorporate the <i>ompA</i> promoter in our final biobrick to regulate the expression of CS. </p>
 
           <div class="container-fluid p-0">
 
           <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 220: Line 231:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/1/1a/T--NCKU_Tainan--ifn_12h.jpg" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/1/1a/T--NCKU_Tainan--ifn_12h.jpg" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/1/1a/T--NCKU_Tainan--ifn_12h.jpg" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/1/1a/T--NCKU_Tainan--ifn_12h.jpg" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 14. OFP expression of sample 1 (<i>P<sub>pspA</sub>-ofp-P<sub>lacI</sub>-ompA/oprF</i>) (BBa_K3771018) and sample 2 (<i>P<sub>pspA</sub>-ofp-P<sub>ompA</sub>-ompA/oprF</i>) (BBa_K3771018)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 15. OFP expression of sample 1 (<i>P<sub>pspA</sub>-ofp-P<sub>lacI</sub>-ompA/oprF</i>) (BBa_K3771018) and sample 2 (<i>P<sub>pspA</sub>-ofp-P<sub>ompA</sub>-ompA/oprF</i>) (BBa_K3771018)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 231: Line 242:
 
                   <h4>Process</h4>
 
                   <h4>Process</h4>
 
                   <p>&emsp;&emsp;In our final biobrick, the production of CS is regulated by the IFN-γ sensing system. For CS expression to be confirmed by western blot, a 6xHis-tag sequence was attached to the 3’ end of the cs sequence. </p>
 
                   <p>&emsp;&emsp;In our final biobrick, the production of CS is regulated by the IFN-γ sensing system. For CS expression to be confirmed by western blot, a 6xHis-tag sequence was attached to the 3’ end of the cs sequence. </p>
                   <p>&emsp;&emsp;First, <i>ofp</i> (<a href="http://parts.igem.org/Part:BBa_K156009" target="_blank">BBa_K156009</a>) in P<i><sub>pspA</sub>-ofp</i> (<a href="http://parts.igem.org/Part:BBa_K3771014" target="_blank">BBa_K3771014</a>) was replaced with the <i>cs</i> enzyme sequence, resulting in P<i><sub>pspA</sub>-cs</i>-6xHis (<a href="http://parts.igem.org/Part:BBa_K3771039" target="_blank">BBa_K3771039</a>). Similar to the construction of plasmids for the IFN-γ assay, P<i><sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771016" target="_blank">BBa_K3771016</a>) was double digested and ligated to the P<i><sub>pspA</sub>-cs</i>-6xHis vector. The final P<i><sub>pspA</sub>-cs</i>-6xHis-P<i><sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771044" target="_blank">BBa_K3771044</a>) is induced by IFN-γ, and its expression was confirmed by western blot (Fig. 15).</p>
+
                   <p>&emsp;&emsp;First, <i>ofp</i> (<a href="http://parts.igem.org/Part:BBa_K156009" target="_blank">BBa_K156009</a>) in P<i><sub>pspA</sub>-ofp</i> (<a href="http://parts.igem.org/Part:BBa_K3771014" target="_blank">BBa_K3771014</a>) was replaced with the <i>cs</i> enzyme sequence, resulting in P<i><sub>pspA</sub>-cs</i>-6xHis (<a href="http://parts.igem.org/Part:BBa_K3771039" target="_blank">BBa_K3771039</a>). Similar to the construction of plasmids for the IFN-γ assay, P<i><sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771016" target="_blank">BBa_K3771016</a>) was double digested and ligated to the P<i><sub>pspA</sub>-cs</i>-6xHis vector. The final P<i><sub>pspA</sub>-cs</i>-6xHis-P<i><sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771044" target="_blank">BBa_K3771044</a>) is induced by IFN-γ, and its expression was confirmed by western blot (Fig. 16).</p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg ">
 
                             <div class="col-lg ">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/5/5a/T--NCKU_Tainan--results_construction_confirmation.jpg" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/5/5a/T--NCKU_Tainan--results_construction_confirmation.jpg" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/b/b7/T--NCKU_Tainan--pspAcspompAompA.jpg" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/b/b7/T--NCKU_Tainan--pspAcspompAompA.jpg" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 15. Confirmation of construction by PCR. M: Marker; Lane 1: <i>pspA</i> promoter (BBa_K3071013) (~218bp); Lane 2: <i>ompA</i> promoter (BBa_K3771011) (~309 bp); Lane 3: <i>ompA/oprF</i> (BBa_K3771009) (~1110bp); Lane 4: <i>cs</i>-6xHis (BBa_K3771012) (~1284 bp)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 16. Confirmation of construction by PCR. M: Marker; Lane 1: <i>pspA</i> promoter (BBa_K3071013) (~218bp); Lane 2: <i>ompA</i> promoter (BBa_K3771011) (~309 bp); Lane 3: <i>ompA/oprF</i> (BBa_K3771009) (~1110bp); Lane 4: <i>cs</i>-6xHis (BBa_K3771012) (~1284 bp)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 247: Line 258:
 
                   <h4>Process</h4>
 
                   <h4>Process</h4>
 
                     <p>&emsp;&emsp;The two plasmids P<i><sub>pspA</sub>-ofp</i>-P<i><sub>lacI</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771017" target="_blank">BBa_K3771017</a>) and P<i><sub>pspA</sub>-ofp</i>-P<i><sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771018" target="_blank">BBa_K3771018</a>) were transformed into <i>ompA</i> gene knockout strain, JW0940, to prevent simultaneous expression of both OmpA (<a href="http://parts.igem.org/Part:BBa_K3771010" target="_blank">BBa_K3771010</a>) and chimeric OmpA/OprF in the same sample. Then, western blot was performed to confirm that the chimeric OmpA/OprF protein can be expressed in the <i>E. coli</i> membrane.</p>
 
                     <p>&emsp;&emsp;The two plasmids P<i><sub>pspA</sub>-ofp</i>-P<i><sub>lacI</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771017" target="_blank">BBa_K3771017</a>) and P<i><sub>pspA</sub>-ofp</i>-P<i><sub>ompA</sub>-ompA/oprF</i> (<a href="http://parts.igem.org/Part:BBa_K3771018" target="_blank">BBa_K3771018</a>) were transformed into <i>ompA</i> gene knockout strain, JW0940, to prevent simultaneous expression of both OmpA (<a href="http://parts.igem.org/Part:BBa_K3771010" target="_blank">BBa_K3771010</a>) and chimeric OmpA/OprF in the same sample. Then, western blot was performed to confirm that the chimeric OmpA/OprF protein can be expressed in the <i>E. coli</i> membrane.</p>
                   <p>&emsp;&emsp;As shown in Fig. 16, MG1655 strain in lane 1 expresses OmpA, the positive control, and serves as comparison to chimeric OmpA/OprF. In lane 2, the ompA gene knockout strain, JW0940, with no transformed plasmid is the negative control. In lanes 3 and 4, chimeric OmpA/OprF (~39 kDa) is successfully expressed in JW0940, albeit in lower amounts compared to that of OmpA (~35kDa). </p>
+
                   <p>&emsp;&emsp;As shown in Fig. 17, MG1655 strain in lane 1 expresses OmpA, the positive control, and serves as comparison to chimeric OmpA/OprF. In lane 2, the ompA gene knockout strain, JW0940, with no transformed plasmid is the negative control. In lanes 3 and 4, chimeric OmpA/OprF (~39 kDa) is successfully expressed in JW0940, albeit in lower amounts compared to that of OmpA (~35kDa). </p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 253: Line 264:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--ompA_wb.jpg" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--ompA_wb.jpg" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--ompA_wb.jpg" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--ompA_wb.jpg" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 16. Confirmation of protein expression by western blot. Lane 1: OmpA (BBa_K3771010) (~35 kDa); Lane 2: N/A (no transformed plasmid) ; Lane 3&4: OmpA/OprF chimeric protein (BBa_K3771009) (~39kDa)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 17. Confirmation of protein expression by western blot. Lane 1: OmpA (BBa_K3771010) (~35 kDa); Lane 2: N/A (no transformed plasmid) ; Lane 3&4: OmpA/OprF chimeric protein (BBa_K3771009) (~39kDa)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 263: Line 274:
 
                     <h4>Process</h4>
 
                     <h4>Process</h4>
 
                     <p>&emsp;&emsp;The plasmid with P<i><sub>pspA</sub>-cs</i>-6xHis-P<i><sub>ompA</sub>-ompA/oprF</i>  (<a href="http://parts.igem.org/Part:BBa_K3771044" target="_blank">BBa_K3771044</a>) was transformed into <i>ompA</i> gene knockout strain JW0940 to prevent OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF. Human IFN-γ concentrations of 600pM and 1200pM were added to bacteria cultures, which were then incubated at 37°C. Bacterial pellets of each sample were collected at 6 and 12 hours after IFN-γ induction. </p>
 
                     <p>&emsp;&emsp;The plasmid with P<i><sub>pspA</sub>-cs</i>-6xHis-P<i><sub>ompA</sub>-ompA/oprF</i>  (<a href="http://parts.igem.org/Part:BBa_K3771044" target="_blank">BBa_K3771044</a>) was transformed into <i>ompA</i> gene knockout strain JW0940 to prevent OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF. Human IFN-γ concentrations of 600pM and 1200pM were added to bacteria cultures, which were then incubated at 37°C. Bacterial pellets of each sample were collected at 6 and 12 hours after IFN-γ induction. </p>
                   <P>&emsp;&emsp;Western blot of the collected samples was performed to confirm the expression of CS enzyme after IFN-γ induction. Although CS enzyme is successfully expressed, the results are not as expected, since even without IFN-γ, CS enzyme is produced (Fig. 17). </p>
+
                   <P>&emsp;&emsp;Western blot of the collected samples was performed to confirm the expression of CS enzyme after IFN-γ induction. Although CS enzyme is successfully expressed, the results are not as expected, since even without IFN-γ, CS enzyme is produced (Fig. 18). </p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 269: Line 280:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/0/07/T--NCKU_Tainan--cs_wb.jpg" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/0/07/T--NCKU_Tainan--cs_wb.jpg" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/0/07/T--NCKU_Tainan--cs_wb.jpg" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/0/07/T--NCKU_Tainan--cs_wb.jpg" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 17. Confirmation of CS (BBa_K3771012)(~46 kDa) expression by western blot. </figcaption>
+
                                     <figcaption class="mt-3">Fig. 18. Confirmation of CS (BBa_K3771012)(~46 kDa) expression by western blot. </figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 295: Line 306:
 
                   <h4>Process</h4>
 
                   <h4>Process</h4>
 
                   <h5>Plasmid construction for <i>In Vitro</i> Enzyme Testing</h5>
 
                   <h5>Plasmid construction for <i>In Vitro</i> Enzyme Testing</h5>
                   <p>&emsp;&emsp;To construct P<i><sub>T7</sub>-jju</i> (<a href="http://parts.igem.org/Part:BBa_K3771079" target="_blank">BBa_K3771079</a>), the <i>jju</i> (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) sequence synthesized by IDT was amplified by PCR and ligated to <i>T7</i> promoter (<a href="http://parts.igem.org/Part:BBa_I719005" target="_blank">BBa_I719005</a>) in the pET28a cloning vector. Similarly, <i>coaBC</i> sequence (<a href="http://parts.igem.org/Part:BBa_K3771001" target="_blank">BBa_K3771001</a>) synthesized by IDT was amplified by PCR and ligated in the same cloning vector. Digestion results are shown in Fig. 18 and 19. </p>
+
                   <p>&emsp;&emsp;To construct P<i><sub>T7</sub>-jju</i> (<a href="http://parts.igem.org/Part:BBa_K3771079" target="_blank">BBa_K3771079</a>), the <i>jju</i> (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) sequence synthesized by IDT was amplified by PCR and ligated to <i>T7</i> promoter (<a href="http://parts.igem.org/Part:BBa_I719005" target="_blank">BBa_I719005</a>) in the pET28a cloning vector. Similarly, <i>coaBC</i> sequence (<a href="http://parts.igem.org/Part:BBa_K3771001" target="_blank">BBa_K3771001</a>) synthesized by IDT was amplified by PCR and ligated in the same cloning vector. Digestion results are shown in Fig. 19 and 20. </p>
 
                     <div class="container-fluid p-0" >
 
                     <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 301: Line 312:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--jjudigestion.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--jjudigestion.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--jjudigestion.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/c/c2/T--NCKU_Tainan--jjudigestion.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 18. Confirmation of  pET28a-T7-JJU by digestion (left). M: Marker; Lane 1: Colony of pET28a-T7-JJU (~6466 bp)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 19. Confirmation of  pET28a-T7-JJU by digestion (left). M: Marker; Lane 1: Colony of pET28a-T7-JJU (~6466 bp)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 307: Line 318:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/5/59/T--NCKU_Tainan--CoaBC-digestion.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/5/59/T--NCKU_Tainan--CoaBC-digestion.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/5/59/T--NCKU_Tainan--CoaBC-digestion.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/5/59/T--NCKU_Tainan--CoaBC-digestion.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 19. Confirmation of  pET28a-T7-CoaBC by digestion (right). M: Marker; Lane 1~3: Different colonies of pET28a-T7-CoaBC (5398 bp)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 20. Confirmation of  pET28a-T7-CoaBC by digestion (right). M: Marker; Lane 1~3: Different colonies of pET28a-T7-CoaBC (5398 bp)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 313: Line 324:
 
                     </div>
 
                     </div>
 
                   <h5>Plasmid construction for <i>In Vivo</i> Enzyme Testing</h5>
 
                   <h5>Plasmid construction for <i>In Vivo</i> Enzyme Testing</h5>
                   <p>&emsp;&emsp;P<i><sub>trc</sub>-csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) plasmid was constructed by ligating the amplified <i>csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771003" target="_blank">BBa_K3771003</a>) fragment to the <i>trc</i> promoter (<a href="http://parts.igem.org/Part:BBa_K864400" target="_blank">BBa_K864400</a>) in the pSUI cloning vector. P<i><sub>trc</sub>-cdo1</i> (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>), cloned into the pSB4K1 vector, and P<i><sub>lacI</sub>-csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771076" target="_blank">BBa_K3771076</a>), cloned into the pSAA vector, were constructed using the same process. Digestion results are shown in Fig. 20, 21, and 22. </p>
+
                   <p>&emsp;&emsp;P<i><sub>trc</sub>-csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) plasmid was constructed by ligating the amplified <i>csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771003" target="_blank">BBa_K3771003</a>) fragment to the <i>trc</i> promoter (<a href="http://parts.igem.org/Part:BBa_K864400" target="_blank">BBa_K864400</a>) in the pSUI cloning vector. P<i><sub>trc</sub>-cdo1</i> (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>), cloned into the pSB4K1 vector, and P<i><sub>lacI</sub>-csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771076" target="_blank">BBa_K3771076</a>), cloned into the pSAA vector, were constructed using the same process. Digestion results are shown in Fig. 21, 22, and 23. </p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg ">
 
                             <div class="col-lg ">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/3/3b/T--NCKU_Tainan--8.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/f/f8/T--NCKU_Tainan--colonycsad.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/0/0d/T--NCKU_Tainan--2.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/0/0d/T--NCKU_Tainan--2.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 20. Confirmation of pSUI-Ptrc-CSAD by digestion (left). M: Marker; Lane 1~3: Different colonies of pSUI-Ptrc-CSAD (3674 bp)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 21. Confirmation of pSUI-<i>P<sub>trc</sub>-csad</i> by digestion (left). M: Marker; Lane 1~3: Different colonies of pSUI-<i>P<sub>trc</sub>-csad</i> (3674 bp)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 328: Line 339:
 
                             <div class="col-lg">
 
                             <div class="col-lg">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/8/8f/T--NCKU_Tainan--9.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/3/31/T--NCKU_Tainan--colonycs.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/a/aa/T--NCKU_Tainan--3.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/a/aa/T--NCKU_Tainan--3.png" alt="" title="" style="width:100%"></a>
                                    <figcaption class="mt-3">Fig. 21. Confirmation of cs fragment by colony PCR (middle). M: Marker; Lane 1~6: Different colonies of pSUI-Ptrc-CS (1272 bp)</figcaption>
+
                                  <figcaption class="mt-3">Fig. 22. Confirmation of <i>cs</i> fragment by colony PCR (middle). M: Marker; Lane 1~6: Different colonies of pSUI-<i>P<sub>trc</sub>-cs</i> (1272 bp)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/f/f1/T--NCKU_Tainan--10.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/a/a2/T--NCKU_Tainan--colonycdo1.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/0/0d/T--NCKU_Tainan--2.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/0/0d/T--NCKU_Tainan--2.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 22. Confirmation of  pSB4KI-Ptrc-CDO1 by digestion (right).M: Marker; Lane 1~3: Different colonies of pSB4KI-Ptrc-CDO1 (5470 bp)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 23. Confirmation of  pSB4KI-<i>P<sub>trc</sub>-cdo1</i> by digestion (right).M: Marker; Lane 1~3: Different colonies of pSB4KI-<i>P<sub>trc</sub>-cdo1</i> (5470 bp)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 347: Line 358:
 
                   <h4>Results</h4>
 
                   <h4>Results</h4>
 
                   <h5><i>In Vitro</i> Test 1: Taurine Production of JJU and CoaBC in BL21(DE3)</h5>
 
                   <h5><i>In Vitro</i> Test 1: Taurine Production of JJU and CoaBC in BL21(DE3)</h5>
                   <p>&emsp;&emsp;P<i><sub>T7</sub>-jju</i> (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) and P<i><sub>T7</sub>-coaBC</i> (<a href="http://parts.igem.org/Part:BBa_K3771080" target="_blank">BBa_K3771080</a>) were each transformed into the BL21(DE3) strain. Supernatants (S) were collected to confirm extracellular enzyme expression and later, taurine production. The proteins in supernatant samples contain folded proteins and enzymes ready to function. On the other hand, bacterial pellets were washed and lysed to prepare whole cell (WC) samples to determine intracellular proteins, which contain a higher concentration of unfolded proteins. JJU and CoaBC expression in both supernatants and whole cell samples were confirmed by SDS-PAGE (Fig. 23).</p>
+
                   <p>&emsp;&emsp;P<i><sub>T7</sub>-jju</i> (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) and P<i><sub>T7</sub>-coaBC</i> (<a href="http://parts.igem.org/Part:BBa_K3771080" target="_blank">BBa_K3771080</a>) were each transformed into the BL21(DE3) strain. Supernatants (S) were collected to confirm extracellular enzyme expression and later, taurine production. The proteins in supernatant samples contain folded proteins and enzymes ready to function. On the other hand, bacterial pellets were washed and lysed to prepare whole cell (WC) samples to determine intracellular proteins, which contain a higher concentration of unfolded proteins. JJU and CoaBC expression in both supernatants and whole cell samples were confirmed by SDS-PAGE (Fig. 24).</p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 353: Line 364:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/8/80/T--NCKU_Tainan--invitro1-PAGE.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/8/80/T--NCKU_Tainan--invitro1-PAGE.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/8/80/T--NCKU_Tainan--invitro1-PAGE.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/8/80/T--NCKU_Tainan--invitro1-PAGE.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 23. Confirmation of protein expression of JJU in BL21(DE3) and CoaBC in BL21(DE3) in soluble protein and whole cell samples. M: Marker; Lane 1: whole cell of JJU in BL21(DE3); Lane 2: soluble protein of JJU in BL21(DE3) (~43 kDa);Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45 kDa) </figcaption>
+
                                     <figcaption class="mt-3">Fig. 24. Confirmation of protein expression of JJU in BL21(DE3) and CoaBC in BL21(DE3) in soluble protein and whole cell samples. M: Marker; Lane 1: whole cell of JJU in BL21(DE3); Lane 2: soluble protein of JJU in BL21(DE3) (~43 kDa);Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45 kDa) </figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 359: Line 370:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/7/70/T--NCKU_Tainan--1223.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/7/70/T--NCKU_Tainan--1223.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/7/70/T--NCKU_Tainan--1223.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/7/70/T--NCKU_Tainan--1223.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 24. Taurine production of JJU in BL21(DE3) and CoaBC in BL21(DE3) in supernatant and whole cell samples.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 25. Taurine production of JJU in BL21(DE3) and CoaBC in BL21(DE3) in supernatant and whole cell samples.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>&emsp;&emsp;2:1 ratio of JJU to CoaBC supernatant volume had the highest taurine production (Fig. 24). Because JJU concentrations were lower, two times as much JJU supernatant volume compared to CoaBC supernatant volume was required to produce a significant amount of taurine. </p>
+
                   <p>&emsp;&emsp;2:1 ratio of JJU to CoaBC supernatant volume had the highest taurine production (Fig. 25). Because JJU concentrations were lower, two times as much JJU supernatant volume compared to CoaBC supernatant volume was required to produce a significant amount of taurine. </p>
 
                   <h3><i>In Vitro</i> Test 2: Taurine Production of JJU in BD7G and CoaBC in BL21(DE3)</h3>
 
                   <h3><i>In Vitro</i> Test 2: Taurine Production of JJU in BD7G and CoaBC in BL21(DE3)</h3>
                   <p>&emsp;&emsp;<p> Since JJU expression in BL21(DE3) strain was not prominent in the supernatant, we performed another <i>in vitro</i> test in which  <i>PT7-coaBC</i>  (<a href="http://parts.igem.org/Part:BBa_K3771080" target="_blank">BBa_K3771080</a>) was transformed into the BL21(DE3) strain, while <i>PT7-jju</i>  (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) was transformed into the BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding<sup>[<a href="#ref4">4</a>]</sup>. SDS-PAGE results confirm JJU and CoaBC expression in all samples (Fig. 25).</p>     
+
                   <p>&emsp;&emsp;Since JJU expression in BL21(DE3) strain was not prominent in the supernatant, we performed another <i>in vitro</i> test in which  <i>PT7-coaBC</i>  (<a href="http://parts.igem.org/Part:BBa_K3771080" target="_blank">BBa_K3771080</a>) was transformed into the BL21(DE3) strain, while <i>PT7-jju</i>  (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) was transformed into the BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding<sup>[<a href="#ref4">4</a>]</sup>. SDS-PAGE results confirm JJU and CoaBC expression in all samples (Fig. 26).</p>     
 
                 <div class="container-fluid p-0" >
 
                 <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 372: Line 383:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/6/63/T--NCKU_Tainan--invitro2-PAGE.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/6/63/T--NCKU_Tainan--invitro2-PAGE.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/6/63/T--NCKU_Tainan--invitro2-PAGE.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/6/63/T--NCKU_Tainan--invitro2-PAGE.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 25. Confirmation of protein expression of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein and whole cell samples. M: Marker; Lane 1: whole cell of JJU in BD7G; Lane 2: soluble protein of JJU in BD7G (~43 kDa); Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45 kDa)</figcaption>
+
                                     <figcaption class="mt-3">Fig. 26. Confirmation of protein expression of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein and whole cell samples. M: Marker; Lane 1: whole cell of JJU in BD7G; Lane 2: soluble protein of JJU in BD7G (~43 kDa); Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45 kDa)</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 378: Line 389:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/9/9f/T--NCKU_Tainan--taurinejjucoabc2.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/9/9f/T--NCKU_Tainan--taurinejjucoabc2.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/9/9f/T--NCKU_Tainan--taurinejjucoabc2.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/9/9f/T--NCKU_Tainan--taurinejjucoabc2.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 26. Taurine production of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein samples.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 27. Taurine production of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein samples.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 385: Line 396:
 
                    
 
                    
 
                    
 
                    
                   <p> P<i><sub>T7</sub>-coaBC</i> (<a href="http://parts.igem.org/Part:BBa_K3771080" target="_blank">BBa_K3771080</a>) was transformed into the BL21(DE3) strain, while P<i><sub>T7</sub>-jju</i>  (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) was transformed into the BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding<sup>[<a href="#ref4">4</a>]</sup>. SDS-PAGE results confirm JJU and CoaBC expression in all samples (Fig. 25).  </p>
+
                   <p>&emsp;&emsp;P<i><sub>T7</sub>-coaBC</i> (<a href="http://parts.igem.org/Part:BBa_K3771080" target="_blank">BBa_K3771080</a>) was transformed into the BL21(DE3) strain, while P<i><sub>T7</sub>-jju</i>  (<a href="http://parts.igem.org/Part:BBa_K3771000" target="_blank">BBa_K3771000</a>) was transformed into the BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding<sup>[<a href="#ref4">4</a>]</sup>. SDS-PAGE results confirm JJU and CoaBC expression in all samples (Fig. 26).  </p>
                   <p>   The whole cell and supernatant JJU and CoaBC samples are collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. In <i>In Vitro</i> Test 1, a greater volume of JJU sample was needed to produce the maximum amount of taurine. However, this time when P<i><sub>T7</sub>-jju</i> was transformed into the BD7G strain, 1:1 ratio of JJU to CoaBC supernatant had the highest taurine production (Fig. 26). This suggests the activity level of JJU does not significantly differ from that of CoaBC, and both are equally crucial and effective in converting L-cysteine to taurine.</p>
+
                   <p>&emsp;&emsp;The whole cell and supernatant JJU and CoaBC samples are collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. In <i>In Vitro</i> Test 1, a greater volume of JJU sample was needed to produce the maximum amount of taurine. However, this time when P<i><sub>T7</sub>-jju</i> was transformed into the BD7G strain, 1:1 ratio of JJU to CoaBC supernatant had the highest taurine production (Fig. 27). This suggests the activity level of JJU does not significantly differ from that of CoaBC, and both are equally crucial and effective in converting L-cysteine to taurine.</p>
 
                   <h3><i>In Vivo</i> Tests for Taurine Production by CS-CSAD-CDO1</h3>
 
                   <h3><i>In Vivo</i> Tests for Taurine Production by CS-CSAD-CDO1</h3>
 
                   <h4>Achievements </h4>
 
                   <h4>Achievements </h4>
Line 395: Line 406:
 
                   <h4>Results</h4>
 
                   <h4>Results</h4>
 
                   <h5><i>In Vivo</i> Test 1: Choosing a Growth Medium</h5>
 
                   <h5><i>In Vivo</i> Test 1: Choosing a Growth Medium</h5>
                   <p>   Since the intestine is not as nutrient-rich as LB (lysogeny broth), we chose to test taurine production in both LB and M9 (minimal salts) mediums. M9 consists of fewer nutrients than LB and more closely mimics the nutrient composition of the human intestine.</p>
+
                   <p>&emsp;&emsp;Since the intestine is not as nutrient-rich as LB (lysogeny broth), we chose to test taurine production in both LB and M9 (minimal salts) mediums. M9 consists of fewer nutrients than LB and more closely mimics the nutrient composition of the human intestine.</p>
                   <p>   First, P<i><sub>trc</sub>-cdo1</i>  (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>), P<i><sub>lacI</sub>-csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771076" target="_blank">BBa_K3771076</a>), and P<i><sub>trc</sub>-cs</i>  (<a href="http://parts.igem.org/Part:BBa_K3771078" target="_blank">BBa_K3771078</a>) were transformed into DH5α strain. In another sample, only P<i><sub>trc</sub>-cdo1</i> and P<i><sub>trc</sub>-csad</i>  (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) were transformed. The two samples were each grown in LB with IPTG inducer (LB+), M9 with IPTG inducer (M9+) , and M9 without IPTG inducer (M9-) mediums. </p>
+
                   <p>&emsp;&emsp;First, P<i><sub>trc</sub>-cdo1</i>  (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>), P<i><sub>lacI</sub>-csad</i> (<a href="http://parts.igem.org/Part:BBa_K3771076" target="_blank">BBa_K3771076</a>), and P<i><sub>trc</sub>-cs</i>  (<a href="http://parts.igem.org/Part:BBa_K3771078" target="_blank">BBa_K3771078</a>) were transformed into DH5α strain. In another sample, only P<i><sub>trc</sub>-cdo1</i> and P<i><sub>trc</sub>-csad</i>  (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) were transformed. The two samples were each grown in LB with IPTG inducer (LB+), M9 with IPTG inducer (M9+) , and M9 without IPTG inducer (M9-) mediums. </p>
                   <p>   The samples’ respective growth curves are shown in Fig. 27 and 28. Interestingly, the sample with all three enzymes (P<i><sub>trc</sub>-cdo1</i> +P<i><sub>lacI<sub>-csad</i> +P<i><sub>trc</sub>-cs</i>) had a lower growth rate in M9+ medium than in M9- medium. In the sample with two enzymes (P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i>), M9 medium with or without an inducer added produced similar growth curves. Both samples grew best in LB (Fig. 27, 28).</p>
+
                   <p>&emsp;&emsp;The samples’ respective growth curves are shown in Fig. 28 and 29. Interestingly, the sample with all three enzymes (P<i><sub>trc</sub>-cdo1</i> +P<i><sub>lacI<sub>-csad</i> +P<i><sub>trc</sub>-cs</i>) had a lower growth rate in M9+ medium than in M9- medium. In the sample with two enzymes (P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i>), M9 medium with or without an inducer added produced similar growth curves. Both samples grew best in LB (Fig. 28, 29).</p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg">
 
                             <div class="col-lg">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/4/4f/T--NCKU_Tainan--123456.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/4f/T--NCKU_Tainan--123456.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/b/b6/T--NCKU_Tainan--4.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/b/b6/T--NCKU_Tainan--4.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 27. Growth curve of P<i><sub>trc</sub>-cdo1</i> +P<i><sub>lacI</sub>-csad</i> +P<i><sub>trc</sub>-cs</i> in different growth mediums.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 28. Growth curve of P<i><sub>trc</sub>-cdo1</i> +P<i><sub>lacI</sub>-csad</i> +P<i><sub>trc</sub>-cs</i> in different growth mediums.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/3/3c/T--NCKU_Tainan--bar3.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/3/3c/T--NCKU_Tainan--bar3.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/6/6e/T--NCKU_Tainan--5-5.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/6/6e/T--NCKU_Tainan--5-5.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 28. Growth curve of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in different growth mediums.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 29. Growth curve of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in different growth mediums.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>   Taurine concentrations were highest at 12 hours when grown in LB (Fig. 29, 30). However, at 24 hours, taurine levels in all three mediums were very low. To more easily detect and quantify taurine production, we decided to use LB medium for the rest of the in vivo taurine production experiments. In addition, because there is no difference in taurine produced with or without CS, we decided to conduct the rest of the experiments with CSAD and CDO1 enzymes. In the future, we hope to perform more experiments with the CS enzyme. </p>
+
                   <p>&emsp;&emsp;Taurine concentrations were highest at 12 hours when grown in LB (Fig. 30, 31). However, at 24 hours, taurine levels in all three mediums were very low. To more easily detect and quantify taurine production, we decided to use LB medium for the rest of the in vivo taurine production experiments. In addition, because there is no difference in taurine produced with or without CS, we decided to conduct the rest of the experiments with CSAD and CDO1 enzymes. In the future, we hope to perform more experiments with the CS enzyme. </p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg">
 
                             <div class="col-lg">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/4/40/T--NCKU_Tainan--Taurine3.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/40/T--NCKU_Tainan--Taurine3.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/6/6f/T--NCKU_Tainan--6.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/6/6f/T--NCKU_Tainan--6.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 29. Taurine production of P<i><sub>trc</sub>-cdo1</i> +P<i><sub>lacI</sub>-csad</i> +P<i><sub>trc</sub>-cs</i> in different growth mediums.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 30. Taurine production of P<i><sub>trc</sub>-cdo1</i> +P<i><sub>lacI</sub>-csad</i> +P<i><sub>trc</sub>-cs</i> in different growth mediums.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/3/3c/T--NCKU_Tainan--bar3.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/3/3c/T--NCKU_Tainan--bar3.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/0/07/T--NCKU_Tainan--7.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/0/07/T--NCKU_Tainan--7.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 30. Taurine production of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in different growth mediums.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 31. Taurine production of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in different growth mediums.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 432: Line 443:
 
                     </div>
 
                     </div>
 
                     <h5><i>In Vivo</i> Test 2: Determining Extracellular Taurine Concentrations in Different <i>E. coli</i> Strains</h5>
 
                     <h5><i>In Vivo</i> Test 2: Determining Extracellular Taurine Concentrations in Different <i>E. coli</i> Strains</h5>
                   <p>   Once the taurine production enzymes are expressed, they can be found intracellularly and extracellularly, resulting in different taurine concentrations inside and outside the bacteria. To determine extracellular taurine, the supernatants of the bacteria culture samples are collected, and taurine production was compared between different knockout strains. </p>
+
                   <p>&emsp;&emsp;Once the taurine production enzymes are expressed, they can be found intracellularly and extracellularly, resulting in different taurine concentrations inside and outside the bacteria. To determine extracellular taurine, the supernatants of the bacteria culture samples are collected, and taurine production was compared between different knockout strains. </p>
                     <p>   For sample preparation, P<i><sub>trc</sub>-cdo1</i>  (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>) and P<i><sub>trc</sub>-csad</i>  (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) are each transformed into <i>∆tauD</i> (taurine dioxygenase gene deletion), <i>∆tauD-∆ompA</i> (<i>tauD</i> and <i>ompA</i> gene deletion) double knockout (DkO), and TOP10 strains. In the <i>∆tauD</i> strain, the deletion of the taurine dioxygenase gene prevents taurine from degradation by catabolic enzymes in the cell. In addition to the <i>tauD</i> gene deletion, the <i>ompA</i> gene is also knocked out in the <i>∆tauD-∆ompA</i> double knockout strain, which prevents OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF for the IFN-γ sensing system. TOP10 strain contains no gene deletions and serves as the control. More information about how the <i>tauD</i> and <i>ompA</i> genes were knocked out can be found in the <a href="https://2021.igem.org/Team:NCKU_Tainan/Engineering" target="_blank">Engineering</a> page.</p>
+
                     <p>&emsp;&emsp;For sample preparation, P<i><sub>trc</sub>-cdo1</i>  (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>) and P<i><sub>trc</sub>-csad</i>  (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) are each transformed into <i>∆tauD</i> (taurine dioxygenase gene deletion), <i>∆tauD-∆ompA</i> (<i>tauD</i> and <i>ompA</i> gene deletion) double knockout (DkO), and TOP10 strains. In the <i>∆tauD</i> strain, the deletion of the taurine dioxygenase gene prevents taurine from degradation by catabolic enzymes in the cell. In addition to the <i>tauD</i> gene deletion, the <i>ompA</i> gene is also knocked out in the <i>∆tauD-∆ompA</i> double knockout strain, which prevents OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF for the IFN-γ sensing system. TOP10 strain contains no gene deletions and serves as the control. More information about how the <i>tauD</i> and <i>ompA</i> genes were knocked out can be found in the <a href="https://2021.igem.org/Team:NCKU_Tainan/Engineering" target="_blank">Engineering</a> page.</p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg ">
 
                             <div class="col-lg ">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/2/20/T--NCKU_Tainan--growth2.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/2/20/T--NCKU_Tainan--growth2.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/5/5a/T--NCKU_Tainan--8-8.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/5/5a/T--NCKU_Tainan--8-8.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 31.  Growth curve of <i>Ptrc-cdo1</i>+<i>Ptrc-csad</i> in different strains.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 32.  Growth curve of <i>Ptrc-cdo1</i>+<i>Ptrc-csad</i> in different strains.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
                         </div>`
+
                         </div>
 
                     </div>
 
                     </div>
                     <p>   For <i>∆tauD</i> and DkO strains, OD<sub>600</sub> of samples with no transformed plasmid were also recorded, serving as the negative control group (Fig. 32, 33). Even with a transformed plasmid, the bacteria still show adequate growth. </p>
+
                     <p>&emsp;&emsp;For <i>∆tauD</i> and DkO strains, OD<sub>600</sub> of samples with no transformed plasmid were also recorded, serving as the negative control group (Fig. 33, 34). Even with a transformed plasmid, the bacteria still show adequate growth. </p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg">
 
                             <div class="col-lg">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/2/23/T--NCKU_Tainan--taud1.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/2/23/T--NCKU_Tainan--taud1.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/9/96/T--NCKU_Tainan--9-9.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/9/96/T--NCKU_Tainan--9-9.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 32. Growth curve of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in <i>∆tauD</i>.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 33. Growth curve of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in <i>∆tauD</i>.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href=" https://static.igem.org/mediawiki/2021/7/7d/T--NCKU_Tainan--DKO2.png" target="_blank" style="width:70%"><img src=" https://static.igem.org/mediawiki/2021/7/7d/T--NCKU_Tainan--DKO2.png" alt="" title="" style="width:100%"></a>
+
                                     <a href=" https://static.igem.org/mediawiki/2021/c/cc/T--NCKU_Tainan--10-10.png" target="_blank" style="width:70%"><img src=" https://static.igem.org/mediawiki/2021/c/cc/T--NCKU_Tainan--10-10.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 33. Growth curve of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in DkO.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 34. Growth curve of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in DkO.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>   Extracellular CSAD and CDO1 expression at 8 and 10 hours after incubation were confirmed by SDS-PAGE (Fig. 34, 35). </p>
+
                   <p>&emsp;&emsp;Extracellular CSAD and CDO1 expression at 8 and 10 hours after incubation were confirmed by SDS-PAGE (Fig. 35, 36). </p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 467: Line 478:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/4/4a/T--NCKU_Tainan--invivo2-page.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/4a/T--NCKU_Tainan--invivo2-page.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/4/4a/T--NCKU_Tainan--invivo2-page.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/4a/T--NCKU_Tainan--invivo2-page.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 34. Confirmation of protein expression of CDO1 and CSAD in <i>∆tauD</i>, DkO, and top10 at 8 hours. M: Marker; Lane 1: pSUI-P<i><sub>trc</sub>-cdo1</i> and pSUI-P<i><sub>trc</sub>-csad</i> transformed into <i>∆tauD</i>; Lane 2: pSUI-P<i><sub>trc</sub>-cdo1</i> and pSUI-P<i><sub>trc</sub>-csad</i> transformed into DkO; Lane 3: pSUI-P<i><sub>trc</sub>-cdo1</i> and pSUI-P<i><sub>trc</sub>-csad</i> transformed into top10</figcaption>
+
                                     <figcaption class="mt-3">Fig. 35. Confirmation of protein expression of CDO1 and CSAD in <i>∆tauD</i>, DkO, and top10 at 8 hours. M: Marker; Lane 1: pSUI-P<i><sub>trc</sub>-cdo1</i> and pSUI-P<i><sub>trc</sub>-csad</i> transformed into <i>∆tauD</i>; Lane 2: pSUI-P<i><sub>trc</sub>-cdo1</i> and pSUI-P<i><sub>trc</sub>-csad</i> transformed into DkO; Lane 3: pSUI-P<i><sub>trc</sub>-cdo1</i> and pSUI-P<i><sub>trc</sub>-csad</i> transformed into top10</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 473: Line 484:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/4/4c/T--NCKU_Tainan--ex-PAGE2.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/4c/T--NCKU_Tainan--ex-PAGE2.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/4/4c/T--NCKU_Tainan--ex-PAGE2.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/4c/T--NCKU_Tainan--ex-PAGE2.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 35. Confirmation of protein expression of CDO1 and CSAD in <i>∆tauD</i> and DkO at 10 hours. </figcaption>
+
                                     <figcaption class="mt-3">Fig. 36. Confirmation of protein expression of CDO1 and CSAD in <i>∆tauD</i> and DkO at 10 hours. </figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>   Taurine was successfully produced in <i>∆tauD</i>, DKO, and TOP10 strains (Fig. 36)  Taurine concentration is highest at 10 hours after incubation for both the ∆tauD and DKO strains (Fig. 37, 38). After confirming extracellular taurine concentrations by the DkO strain, we continued the following <i>in vivo</i> tests with the DkO strain. </p>
+
                   <p>&emsp;&emsp;Taurine was successfully produced in <i>∆tauD</i>, DKO, and TOP10 strains (Fig. 37)  Taurine concentration is highest at 10 hours after incubation for both the ∆tauD and DKO strains (Fig. 38, 39). After confirming extracellular taurine concentrations by the DkO strain, we continued the following <i>in vivo</i> tests with the DkO strain. </p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 484: Line 495:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/1/18/T--NCKU_Tainan--TP.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/1/18/T--NCKU_Tainan--TP.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/1/18/T--NCKU_Tainan--TP.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/1/18/T--NCKU_Tainan--TP.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 36. Taurine production (extracellular) of CDO1 and CSAD in different strains.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 37. Taurine production (extracellular) of CDO1 and CSAD in different strains.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 493: Line 504:
 
                             <div class="col-lg">
 
                             <div class="col-lg">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/a/a6/T--NCKU_Tainan--dko.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/a/a6/T--NCKU_Tainan--dko.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/2/2f/T--NCKU_Tainan--12-12.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/2/2f/T--NCKU_Tainan--12-12.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 37. Taurine production (extracellular) of CDO1 and CSAD in ∆tauD. </figcaption>
+
                                     <figcaption class="mt-3">Fig. 38. Taurine production (extracellular) of CDO1 and CSAD in ∆tauD. </figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/4/48/T--NCKU_Tainan--taud.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/4/48/T--NCKU_Tainan--taud.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/9/93/T--NCKU_Tainan--11-11.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/9/93/T--NCKU_Tainan--11-11.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 38. Taurine production (extracellular) of CDO1 and CSAD in DkO.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 39. Taurine production (extracellular) of CDO1 and CSAD in DkO.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
Line 506: Line 517:
 
                     </div>
 
                     </div>
 
                   <h5><i>In Vivo</i> Test 3: Determining Intracellular Taurine Concentration in the DKO Strain</h5>
 
                   <h5><i>In Vivo</i> Test 3: Determining Intracellular Taurine Concentration in the DKO Strain</h5>
                   <p>   To further understand the bacteria’s taurine production, we conducted another <i>in vivo</i> experiment to determine intracellular taurine concentration in the DkO and TOP10 strains. Instead of measuring taurine concentrations in the supernatants of the samples as we did for extracellular concentrations, intracellular taurine concentrations were determined by conducting HPLC on lysed bacterial pellets of each sample.</p>
+
                   <p>&emsp;&emsp;To further understand the bacteria’s taurine production, we conducted another <i>in vivo</i> experiment to determine intracellular taurine concentration in the DkO and TOP10 strains. Instead of measuring taurine concentrations in the supernatants of the samples as we did for extracellular concentrations, intracellular taurine concentrations were determined by conducting HPLC on lysed bacterial pellets of each sample.</p>
                     <p>   For sample preparation, P<i><sub>trc</sub>-cdo1</i>  (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>) and P<i><sub>trc</sub>-csad</i>  (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) are each transformed into the DKO strain and TOP10 strain. Growth curves in each of the strains are shown in Fig. 39.</p>
+
                     <p>&emsp;&emsp;For sample preparation, P<i><sub>trc</sub>-cdo1</i>  (<a href="http://parts.igem.org/Part:BBa_K3771075" target="_blank">BBa_K3771075</a>) and P<i><sub>trc</sub>-csad</i>  (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) are each transformed into the DKO strain and TOP10 strain. Growth curves in each of the strains are shown in Fig. 40.</p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg ">
 
                             <div class="col-lg ">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/6/69/T--NCKU_Tainan--picture1.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/6/69/T--NCKU_Tainan--picture1.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/4/4d/T--NCKU_Tainan--13-13.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/4/4d/T--NCKU_Tainan--13-13.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 39. Growth curves of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in DkO and top10. </figcaption>
+
                                     <figcaption class="mt-3">Fig. 40. Growth curves of P<i><sub>trc</sub>-cdo1</i>+P<i><sub>trc</sub>-csad</i> in DkO and top10. </figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>   Expression of CSAD and CDO1 in both supernatant and whole cell samples was confirmed by SDS-PAGE (Fig. 40). </p>
+
                   <p>&emsp;&emsp;Expression of CSAD and CDO1 in both supernatant and whole cell samples was confirmed by SDS-PAGE (Fig. 41). </p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 524: Line 535:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href=" https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--in-PAGE.png" target="_blank" style="width:70%"><img src=" https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--in-PAGE.png" alt="" title="" style="width:100%"></a>
 
                                     <a href=" https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--in-PAGE.png" target="_blank" style="width:70%"><img src=" https://static.igem.org/mediawiki/2021/a/a3/T--NCKU_Tainan--in-PAGE.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 40. Confirmation of protein expression of CDO1 and CSAD in DkO and TOP10.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 41. Confirmation of protein expression of CDO1 and CSAD in DkO and TOP10.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/8/84/T--NCKU_Tainan--picture2.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/8/84/T--NCKU_Tainan--picture2.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/c/c1/T--NCKU_Tainan--14-14.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/c/c1/T--NCKU_Tainan--14-14.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 41. Taurine production (intracellular and extracellular) of CDO1 and CSAD in DkO and TOP10.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 42. Taurine production (intracellular and extracellular) of CDO1 and CSAD in DkO and TOP10.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>   To determine intracellular taurine concentration, HPLC was conducted on the whole cell samples, which contain all soluble proteins within the bacteria. Although CSAD expression is higher in the supernatant sample of the TOP10 strain than in the DKO strain according to SDS-PAGE results (Fig. 40), DKO strain still produced more taurine than the TOP10 strain (Fig. 41). This proves that the deletion of the <i>tauD</i> gene is crucial in increasing taurine concentrations.</p>
+
                   <p>&emsp;&emsp;To determine intracellular taurine concentration, HPLC was conducted on the whole cell samples, which contain all soluble proteins within the bacteria. Although CSAD expression is higher in the supernatant sample of the TOP10 strain than in the DKO strain according to SDS-PAGE results (Fig. 41), DKO strain still produced more taurine than the TOP10 strain (Fig. 42). This proves that the deletion of the <i>tauD</i> gene is crucial in increasing taurine concentrations.</p>
 
                   <h5><i>In Vivo</i> Test 4: Taurine Production Under the Regulation of the Oxidative Stress Sensing System</h5>
 
                   <h5><i>In Vivo</i> Test 4: Taurine Production Under the Regulation of the Oxidative Stress Sensing System</h5>
                   <p>   From the previous <i>in vivo</i> tests, we proved that the DKO strain with our transformed plasmids can successfully express CDO1 and CSAD and produce taurine. In the final <i>in vivo</i> test, the <i>trc</i> promoter in P<i><sub>trc</sub>-csad</i> was changed to the <i>soxS</i> promoter to determine extracellular taurine production under the regulation of the oxidative stress sensing system.</p>
+
                   <p>&emsp;&emsp;From the previous <i>in vivo</i> tests, we proved that the DKO strain with our transformed plasmids can successfully express CDO1 and CSAD and produce taurine. In the final <i>in vivo</i> test, the <i>trc</i> promoter in P<i><sub>trc</sub>-csad</i> was changed to the <i>soxS</i> promoter to determine extracellular taurine production under the regulation of the oxidative stress sensing system.</p>
                     <p>   For sample preparation, P<i><sub>trc</sub>-cdo1</i> (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) and <i>soxR</i>-P<i><sub>soxS</sub>-csad</i> of the oxidative stress sensing system were both transformed into the DKO strain. Since IPTG is not naturally found in the human body, lactose was also added as an inducer instead of IPTG to consider taurine production in the intestine. Paraquat was added to induce the oxidative stress system. The growth curve is shown in Fig. 42 below.</p>
+
                     <p>&emsp;&emsp;For sample preparation, P<i><sub>trc</sub>-cdo1</i> (<a href="http://parts.igem.org/Part:BBa_K3771077" target="_blank">BBa_K3771077</a>) and <i>soxR</i>-P<i><sub>soxS</sub>-csad</i> of the oxidative stress sensing system were both transformed into the DKO strain. Since IPTG is not naturally found in the human body, lactose was also added as an inducer instead of IPTG to consider taurine production in the intestine. Paraquat was added to induce the oxidative stress system. The growth curve is shown in Fig. 43 below.</p>
 
                   <div class="container-fluid p-0">
 
                   <div class="container-fluid p-0">
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
 
                             <div class="col-lg ">
 
                             <div class="col-lg ">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/3/3d/T--NCKU_Tainan--picture3.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/3/3d/T--NCKU_Tainan--picture3.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/d/de/T--NCKU_Tainan--15-15.png" target="_blank" style="width:50%"><img src="https://static.igem.org/mediawiki/2021/d/de/T--NCKU_Tainan--15-15.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 42. Growth curve of P<i><sub>trc</sub>-cdo1</i> + <i>soxR</i>-P<i><sub>soxS</sub>-csad</i> in DkO.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 43. Growth curve of P<i><sub>trc</sub>-cdo1</i> + <i>soxR</i>-P<i><sub>soxS</sub>-csad</i> in DkO.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>   CSAD and CDO1 expression after 8 hours of incubation was successful as shown in the SDS-PAGE results (Fig. 43). </p>
+
                   <p>&emsp;&emsp;CSAD and CDO1 expression after 8 hours of incubation was successful as shown in the SDS-PAGE results (Fig. 44). </p>
 
                   <div class="container-fluid p-0" >
 
                   <div class="container-fluid p-0" >
 
                         <div class="row no-gutters">
 
                         <div class="row no-gutters">
Line 555: Line 566:
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                     <a href="https://static.igem.org/mediawiki/2021/e/ea/T--NCKU_Tainan--invivo4-PAGE.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/e/ea/T--NCKU_Tainan--invivo4-PAGE.png" alt="" title="" style="width:100%"></a>
 
                                     <a href="https://static.igem.org/mediawiki/2021/e/ea/T--NCKU_Tainan--invivo4-PAGE.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/e/ea/T--NCKU_Tainan--invivo4-PAGE.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 43. Confirmation of protein expression of CDO1 and CSAD with expression of CSAD regulated by <i>soxS</i> promoter in DkO.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 44. Confirmation of protein expression of CDO1 and CSAD with expression of CSAD regulated by <i>soxS</i> promoter in DkO.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                             <div class="col-lg d-flex justify-content-center align-items-center">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
 
                                 <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3">
                                     <a href="https://static.igem.org/mediawiki/2021/2/2e/T--NCKU_Tainan--picture4.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/2/2e/T--NCKU_Tainan--picture4.png" alt="" title="" style="width:100%"></a>
+
                                     <a href="https://static.igem.org/mediawiki/2021/b/bd/T--NCKU_Tainan--16-16.png" target="_blank" style="width:70%"><img src="https://static.igem.org/mediawiki/2021/b/bd/T--NCKU_Tainan--16-16.png" alt="" title="" style="width:100%"></a>
                                     <figcaption class="mt-3">Fig. 44. Taurine production (extracellular) of CDO1 and CSAD with expression of CSAD regulated by <i>soxS</i> promoter in DkO.</figcaption>
+
                                     <figcaption class="mt-3">Fig. 45. Taurine production (extracellular) of CDO1 and CSAD with expression of CSAD regulated by <i>soxS</i> promoter in DkO.</figcaption>
 
                                 </figure>
 
                                 </figure>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
                   <p>   The oxidative stress sensing system successfully expressed CSAD which aided in the production of taurine. Although having a lower taurine concentration than the IPTG-induced sample, the lactose-induced sample proves that the oxidative sensing system also has the potential to activate the bacteria’s taurine production in the human intestine (Fig. 44). </p>
+
                   <p>&emsp;&emsp;The oxidative stress sensing system successfully expressed CSAD which aided in the production of taurine. Although having a lower taurine concentration than the IPTG-induced sample, the lactose-induced sample proves that the oxidative sensing system also has the potential to activate the bacteria’s taurine production in the human intestine (Fig. 45). </p>
                   <p>   In conclusion, from the experiment data collected through four <i>in vivo</i> tests, we proved that our bacteria with the <i>tauD</i> gene deletion can successfully produce taurine when under oxidative stress. To increase <i>E. coli</i>’s specificity in detecting and responding to depressive symptoms, we hope to exchange the lactose-induced <i>trc</i> promoter with the biobrick of the IFN-γ sensing system for the regulation of CDO1 expression. </p>
+
                   <p>&emsp;&emsp;In conclusion, from the experiment data collected through four <i>in vivo</i> tests, we proved that our bacteria with the <i>tauD</i> gene deletion can successfully produce taurine when under oxidative stress. To increase <i>E. coli</i>’s specificity in detecting and responding to depressive symptoms, we hope to exchange the lactose-induced <i>trc</i> promoter with the biobrick of the IFN-γ sensing system for the regulation of CDO1 expression. </p>
 
                    
 
                    
 
                    
 
                    

Latest revision as of 21:07, 21 October 2021



Menbles Production Experiments

Goal

  To test whether Menbles final product can effectively protect E. coli Nissle 1917 under different pH values of milk tea, and to compare which bubble size is the most capable to protect our bacteria.

Achievements

1. Proved that the bubble is effective to protect the bacteria inside by minimizing loss of bacteria, in the pH conditions of milk tea.

2. Identified which bubble size has the best structure based on recovery rates.

Process

  After we decided on sodium alginate and calcium chloride as the raw material for Menbles, we conducted several experiments to test the number of bacteria recovered from the bubble at different pH levels of milk tea (4.5, 5.0, 5.5, 7.0). Menbles is produced by mixing 2 ml of freshly cultured E. coli Nissle 1917 (OD600 = 1) with 50 ml of alginate solution, then using different sizes of laboratory pipettes we dripped 2.5 ml of the solution drop by drop into calcium chloride solution. As the result of different pipette sizes being used, there are three different sizes of the bubble, with the volumes approximately equal to 14.14 mm3 (Large), 4.19 mm3 (Medium), and 1.77 mm3 (Small).

Fig. 1. (A) 14.14 mm3 (Large) bubble (B) 4.19 mm3 (Medium) bubble (C) 1.77 mm3 (Small) bubble
Fig. 2. Menbles Experiment Procedure

  Then, the bubbles were extracted from calcium chloride solution through filtration, which would be equally distributed and submerged into 12.5 ml of disodium hydrogen diphosphate buffer with 4 different pH levels for 2 hours at room temperature.

  After the bubbles were submerged for 2 hours, 60 μl of supernatant from every pH sample was smeared culture into LB plate medium, and the rest of the bubbles were separated from the buffer than would be crushed with the compression of a syringe. The crushed bubble should be submerged back into its original buffer, then 60 μl of supernatant samples were smeared again to another LB medium. Negative controls were also smeared into LB medium which involves buffer without any bubble present to identify any possible contamination.

  After the plates were incubated for 12 hours at 37°C, CFU quantification was conducted to determine the bacteria recovery rate from the bubble. By calculating the amount of bacteria supposed to be inside the bubble in each pH buffer, we can approximate the percentage of bacteria recovered both in the supernatant and the crushed bubble. The results shown in Fig. 3. are the bacteria recovery rate of the large, medium, and small bubbles, with additional negative control plates did not grow any colonies, so the results obtained are devoid of any contamination.

Fig. 3. The recovery percentage of E. coli Nissle 1917 in bubbles with volume 14.14 mm³ (Large), 4.19 mm³ (Medium), and 1.77 mm³ (Small).

  Based on the results shown in Fig. 3, we concluded that the bubble with a volume of 4.19 mm3 (Medium) delivers the best results due to its stable recovery rate and suits our hypothesis of a lower pH will lower down the bacteria loss.


Oxidative Stress Sensing

Plasmid Construction for Oxidative Stress Assay

Achievement

1. Construction of the plasmid containing different promoters that can detect oxidative stress.

Process

   In E. coli, there are two main promoters that can detect oxidative stress, the katG promoter (PkatG) (BBa_K3771047) and the soxS promoter (PsoxS) (BBa_K3771048). To determine which promoter to use in our final biobrick in order to express the taurine-producing enzyme, an oxidative stress assay is essential. Hence, we need to construct plasmids with different promoters and utilize the reporter, sfGFP, to determine the intensity and sensitivity of both promoters.

  First, we conducted PCR to amplify the fragment of PkatG, PsoxS, and soxR gene with PsoxS from the chromosome of E. coli MG1655. SoxR is a transcriptional activator of PsoxS. The fragments were used to replace J23100 promoter in pSAA-J23100-sfgfp (BBa_K3771050). We obtained three new plasmids, pSAA-PkatG-sfgfp (BBa_K3771091), pSAA-PsoxS-sfgfp (BBa_K3771092), and pSAA-soxR-PsoxS-sfgfp (BBa_K3771093). To ensure the correctness of the sequence, we conducted colony PCR after transformation and the result showed that the plasmid contains the correct sequence (Fig. 4).

Fig. 4. The electrophoresis result of colony PCR of (A) pSAA-PkatG-sfgfp (BBa_K3771091), (B) pSAA-PsoxS-sfgfp, (BBa_K3771092), and (C) pSAA-soxR-PsoxS-sfgfp (BBa_K3771093). (A) M: Marker; Lane 1, 2: pSAA-PkatG-sfgfp (2629 bp); Lane 3: pSAA-J23100-sfgfp (2537 bp).​ (B) M: Marker; Lane 1: pSAA-J23100-sfgfp (2537 bp); Lane 2, 3: pSAA-PsoxS-sfgfp (3122 bp). (C) M: Marker; Lane 1, 2: pSAA-soxR-PsoxS-sfgfp (3327 bp); Lane 3: pSAA-PsoxS-sfgfp (2691 bp).

Oxidative Stress Assay

Achievement

1. Compared the intensity and sensitivity of different promoters under the stimulation by oxidative stress.

2. Selected a suitable promoter for regulating the expression of L-cysteine sulfinic acid decarboxylase (CSAD).

Process

  We compared the relative fluorescence intensity of sfGFP expressed by different promoters when induced by different concentrations of paraquat (PQ). Paraquat can react with oxygen to produce various types of reactive oxygen species (ROS), such as superoxide radical (O2•), hydrogen peroxide (H2O2), and hydroxyl radical (OH•)[5], which is used to simulate abnormal oxidative stress in the intestines of stressed individuals.

  Over a period of 4.5 hours after paraquat was added, the relative fluorescence intensity was measured. J23100, a constitutive promoter, being the positive control, shows no difference in sfGFP expression level between the samples with and without paraquat. The activity of PsoxS (BBa_K3771048) is higher than that of PkatG (BBa_K3771047), but the activity is greatest when the SoxR transcription factor (BBa_K3771100) is added in the construction together with PsoxS (Fig. 5 and 6).

Fig. 5. sfGFP expression under high concentration of PQ
Fig. 6. sfGFP expression under lower concentration of PQ. The comparison of different promoter strengths by relative fluorescence intensity after 4.5-hour incubation with paraquat in various concentrations was shown in these two pictures.

  Another oxidative stress assay was performed only with SoxR and PsoxS promoter to determine the efficiency of this detection system. The sfGFP level was measured hourly during the 4.5 hours after paraquat induction, and results showed that even low concentrations of paraquat were able to activate the detection system (Fig. 7 and 8).

Fig. 7. sfGFP expression under low concentration of PQ.
Fig. 8. sfGFP expression under high concentration of PQ. Relative fluorescence intensity of soxR-PsoxS after 4.5-hour incubation with paraquat in various concentrations was shown in these two pictures.

Plasmid Construction for CSAD Enzyme Expression

Achievements

1. Construction of the plasmid containing the soxRS regulon and the csad gene.

Process

  After confirming the function of soxR-PsoxS, the coding sequence of sfGFP was replaced with the csad gene (BBa_K3771008), resulting in a new plasmid - pSAA-soxR-PsoxS-csad-6xHis (BBa_K3771097). This plasmid is essential for producing taurine in our project, and the 6xHis-tag was designed for detecting the expressed protein through western blot. We conducted colony PCR after transformation to verify whether E. coli uptook the correct plasmid. The size of the PCR product was as expected (Fig. 9). The plasmid was also confirmed by sequencing and has no mutations.

Fig. 9. The electrophoresis result of colony PCR of plasmid pSAA-soxR-PsoxS-csad-6xHis. (BBa_K3771097) M: Marker; Lane 1: pSAA-soxR-PsoxS-sfgfp (1050 bp); Lane 2, 3: pSAA-soxR-PsoxS-csad-6xHis (1829 bp).

Enzyme (CSAD) Production

Achievements

1. Confirmation of CSAD (BBa_K3771008) enzyme expression under oxidative stress by western blot.

Process

  To confirm that the CSAD enzyme is successfully expressed when induced by paraquat, the western blot was performed. When the OD600 of the bacterial culture reached 0.5, we added 0.1 mM paraquat into the culture and collected samples at 2, 4, 6 hours after paraquat was added. The result confirmed that CSAD was expressed under oxidative stress. The sample collected at 6 hours after paraquat was added had the greatest expression, and CSAD expression increases as the time allowed for paraquat to induce the SoxS promoter increases (Fig. 10).

Fig. 10. The western blot result. CSAD (~55 kDa); –: control; PQ: 0.1 mM paraquat.

Interferon-gamma Sensing System and Production

Plasmid Construction for IFN-γ Induction Assay

Achievements

1. Constructed PpspA-ofp-PlacI-ompA/oprF (BBa_K3771017) and PpspA-ofp-PompA-ompA/oprF (BBa_K3771018) plasmids for the IFN-γ induction assay

Process

  For the IFN-γ induction assay, OFP is used as the reporter to compare the strengths of the lacI promoter (BBa_R0010) and the ompA promoter (BBa_K3771011). Therefore, two plasmids with the respective promoters were constructed, while also containing the pspA promoter (BBa_K3071013) required for the activation of the IFN-γ sensing system.

  First, the pspA promoter synthesized by IDT was amplified by PCR and then ligated to the ofp gene (BBa_K156009), already present in our starting pUC cloning vector, resulting in PpspA-ofp (BBa_K3771014). To construct PlacI-ompA/oprF (BBa_K3771015), lacI promoter in our starting pUC cloning vector, was ligated with the ompA/oprF fragment (BBa_K3771009) synthesized by IDT. We then cloned the ompA promoter sequence (BBa_K3771011) from E. coli MG1655 and replaced lacI promoter with ompA promoter, resulting in PompA-ompA/oprF (BBa_K3771016).

  Both the PlacI-ompA/oprF (BBa_K3771015) and PompA-ompA/oprF (BBa_K3771016) fragments were double digested and ligated to the PpspA-ofp vector (BBa_K3771014), respectively, which formed the final plasmids required for the IFN-γ assay: PpspA-ofp-PlacI-ompA/oprF (BBa_K3771017) and PpspA-ofp-PompA-ompA/oprF (BBa_K3771018) plasmids.

Fig. 11. Confirmation of construction by PCR. (Left) M: Marker; Lane 1: pspA promoter (BBa_K3071013) (~218bp); Lane 2: ompA/oprF (BBa_K3771009) (~1110bp)
Fig. 12. M: Marker; Lane 1: pspA promoter (~218bp); Lane 2: ompA promoter (BBa_K3771011) (~309 bp); Lane 3: ompA/oprF (~1110bp)

IFN-γ Induction Assay

Achievements

1. Selected a suitable promoter for regulating the expression of chimeric OmpA/OprF protein

2. Determined the minimum IFN-γ concentration required for activation of the sensing system

3. Determined the time required for the system to produce a significant difference in protein expression

Process

  The two plasmids PpspA-ofp-PlacI-ompA/oprF (BBa_K3771017) and PpspA-ofp-PompA-ompA/oprF (BBa_K3771018) were transformed into ompA gene knockout strain, JW0940, to prevent OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF. Human IFN-γ of concentrations 300 pM and 600 pM were added to bacteria cultures to induce the system. OFP expression (RFU) was recorded using a microplate reader and normalized by OD600. As shown in Fig. 13 and 14, starting at around 12 hours after induction, OFP expression of both samples increased dramatically.

Fig. 13. OFP expression of PpspA-ofp-PlacI-ompA/oprF (sample 1) (BBa_K3771017)
Fig. 14. OFP expression of PpspA-ofp-PompA-ompA/oprF (sample 2) (BBa_K3771018)

  As presented in Fig. 15, at 12 hours after induction, sample 2 (PpspA-ofp-PompA-ompA/oprF) (BBa_K3771018) with the addition of 600 pM IFN-γ had higher OFP expression than that of sample 1 (PpspA-ofp-PlacI-ompA/oprF) (BBa_K3771017). Since ompA promoter stimulates higher protein expression than lacI promoter, we decided to incorporate the ompA promoter in our final biobrick to regulate the expression of CS.

Fig. 15. OFP expression of sample 1 (PpspA-ofp-PlacI-ompA/oprF) (BBa_K3771018) and sample 2 (PpspA-ofp-PompA-ompA/oprF) (BBa_K3771018)

Plasmid Construction for CS Enzyme Expression

Achievements

1. Completed construction of the plasmid PpspA-cs-6xHis-PompA-ompA/oprF (BBa_K3771044) for confirming expression of CS (BBa_K3771012) when induced by IFN-γ

Process

  In our final biobrick, the production of CS is regulated by the IFN-γ sensing system. For CS expression to be confirmed by western blot, a 6xHis-tag sequence was attached to the 3’ end of the cs sequence.

  First, ofp (BBa_K156009) in PpspA-ofp (BBa_K3771014) was replaced with the cs enzyme sequence, resulting in PpspA-cs-6xHis (BBa_K3771039). Similar to the construction of plasmids for the IFN-γ assay, PompA-ompA/oprF (BBa_K3771016) was double digested and ligated to the PpspA-cs-6xHis vector. The final PpspA-cs-6xHis-PompA-ompA/oprF (BBa_K3771044) is induced by IFN-γ, and its expression was confirmed by western blot (Fig. 16).

Fig. 16. Confirmation of construction by PCR. M: Marker; Lane 1: pspA promoter (BBa_K3071013) (~218bp); Lane 2: ompA promoter (BBa_K3771011) (~309 bp); Lane 3: ompA/oprF (BBa_K3771009) (~1110bp); Lane 4: cs-6xHis (BBa_K3771012) (~1284 bp)

Chimeric OmpA/OprF Expression

Achievements

1. Confirmed the expression of chimeric OmpA/OprF protein (BBa_K3771009)[1].

Process

  The two plasmids PpspA-ofp-PlacI-ompA/oprF (BBa_K3771017) and PpspA-ofp-PompA-ompA/oprF (BBa_K3771018) were transformed into ompA gene knockout strain, JW0940, to prevent simultaneous expression of both OmpA (BBa_K3771010) and chimeric OmpA/OprF in the same sample. Then, western blot was performed to confirm that the chimeric OmpA/OprF protein can be expressed in the E. coli membrane.

  As shown in Fig. 17, MG1655 strain in lane 1 expresses OmpA, the positive control, and serves as comparison to chimeric OmpA/OprF. In lane 2, the ompA gene knockout strain, JW0940, with no transformed plasmid is the negative control. In lanes 3 and 4, chimeric OmpA/OprF (~39 kDa) is successfully expressed in JW0940, albeit in lower amounts compared to that of OmpA (~35kDa).

Fig. 17. Confirmation of protein expression by western blot. Lane 1: OmpA (BBa_K3771010) (~35 kDa); Lane 2: N/A (no transformed plasmid) ; Lane 3&4: OmpA/OprF chimeric protein (BBa_K3771009) (~39kDa)

Enzyme (CS) Production

Achievements

  Confirmed CS expression by western blot when under regulation of the IFN-γ sensing system.

Process

  The plasmid with PpspA-cs-6xHis-PompA-ompA/oprF (BBa_K3771044) was transformed into ompA gene knockout strain JW0940 to prevent OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF. Human IFN-γ concentrations of 600pM and 1200pM were added to bacteria cultures, which were then incubated at 37°C. Bacterial pellets of each sample were collected at 6 and 12 hours after IFN-γ induction.

  Western blot of the collected samples was performed to confirm the expression of CS enzyme after IFN-γ induction. Although CS enzyme is successfully expressed, the results are not as expected, since even without IFN-γ, CS enzyme is produced (Fig. 18).

Fig. 18. Confirmation of CS (BBa_K3771012)(~46 kDa) expression by western blot.

  In the future, we hope to improve the sensitivity of the pspA promoter (BBa_K3071013) by adding an inhibitor or another transcriptional element to the biobrick so that this sensing system could function more properly according to the fluctuation of IFN-γ.


Proof of Function: Taurine Production

In Vitro vs In Vivo testing

  In vitro testing refers to experiments conducted outside the living organism, while in vivo testing refers to research done in the living organism. To determine taurine production that most closely resembles that of the human intestine, we wanted to conduct in vivo testing of the function of the JJU-CoaBC pathway. However, transformation of both JJU and CoaBC plasmids into one bacteria failed and no colonies grew. Therefore, the JJU and CoaBC plasmids were transformed and cultured separately, and JJU and CoaBC supernatants were added to a reaction solution. In this case, since the substrates are added after incubation, this is considered as in vitro testing of taurine production by JJU and CoaBC.

  In our second attempt to conduct in vivo testing of taurine production, we used the enzymes of the other taurine production pathway, including CSAD, CS, and CDO1 enzymes, which are not naturally found in the human body. There was successful transformation of the three plasmids into one bacterial colony, so in vivo tests of taurine production of these enzymes were conducted.

  The step by step in vitro and in vivo testing of the taurine production pathways are described in the following sections.

Plasmid Construction

Achievements

Constructed the plasmids required for determining the taurine production yield:

1. For in vitro testing: PT7-jju (BBa_K3771079) and PT7-coaBC (BBa_K3771080)

2. For in vivo testing: Ptrc-csad (BBa_K3771077), Ptrc-cdo1 (BBa_K3771075) , Ptrc-cs (BBa_K3771078), and PlacI-csad (BBa_K3771076)

Process

Plasmid construction for In Vitro Enzyme Testing

  To construct PT7-jju (BBa_K3771079), the jju (BBa_K3771000) sequence synthesized by IDT was amplified by PCR and ligated to T7 promoter (BBa_I719005) in the pET28a cloning vector. Similarly, coaBC sequence (BBa_K3771001) synthesized by IDT was amplified by PCR and ligated in the same cloning vector. Digestion results are shown in Fig. 19 and 20.

Fig. 19. Confirmation of pET28a-T7-JJU by digestion (left). M: Marker; Lane 1: Colony of pET28a-T7-JJU (~6466 bp)
Fig. 20. Confirmation of pET28a-T7-CoaBC by digestion (right). M: Marker; Lane 1~3: Different colonies of pET28a-T7-CoaBC (5398 bp)
Plasmid construction for In Vivo Enzyme Testing

  Ptrc-csad (BBa_K3771077) plasmid was constructed by ligating the amplified csad (BBa_K3771003) fragment to the trc promoter (BBa_K864400) in the pSUI cloning vector. Ptrc-cdo1 (BBa_K3771075), cloned into the pSB4K1 vector, and PlacI-csad (BBa_K3771076), cloned into the pSAA vector, were constructed using the same process. Digestion results are shown in Fig. 21, 22, and 23.

Fig. 21. Confirmation of pSUI-Ptrc-csad by digestion (left). M: Marker; Lane 1~3: Different colonies of pSUI-Ptrc-csad (3674 bp)
Fig. 22. Confirmation of cs fragment by colony PCR (middle). M: Marker; Lane 1~6: Different colonies of pSUI-Ptrc-cs (1272 bp)
Fig. 23. Confirmation of pSB4KI-Ptrc-cdo1 by digestion (right).M: Marker; Lane 1~3: Different colonies of pSB4KI-Ptrc-cdo1 (5470 bp)

In Vitro Tests for Taurine Production by JJU-CoaBC

Achievements

1. In vitro Test 1&2: Chose suitable E. coli strains for taurine production of JJU (BBa_K3771000) and CoaBC (BBa_K3771001)enzymes

2. Determined the taurine production of JJU and CoaBC enzymes[2,3]

Results

In Vitro Test 1: Taurine Production of JJU and CoaBC in BL21(DE3)

  PT7-jju (BBa_K3771000) and PT7-coaBC (BBa_K3771080) were each transformed into the BL21(DE3) strain. Supernatants (S) were collected to confirm extracellular enzyme expression and later, taurine production. The proteins in supernatant samples contain folded proteins and enzymes ready to function. On the other hand, bacterial pellets were washed and lysed to prepare whole cell (WC) samples to determine intracellular proteins, which contain a higher concentration of unfolded proteins. JJU and CoaBC expression in both supernatants and whole cell samples were confirmed by SDS-PAGE (Fig. 24).

Fig. 24. Confirmation of protein expression of JJU in BL21(DE3) and CoaBC in BL21(DE3) in soluble protein and whole cell samples. M: Marker; Lane 1: whole cell of JJU in BL21(DE3); Lane 2: soluble protein of JJU in BL21(DE3) (~43 kDa);Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45 kDa)
Fig. 25. Taurine production of JJU in BL21(DE3) and CoaBC in BL21(DE3) in supernatant and whole cell samples.

  2:1 ratio of JJU to CoaBC supernatant volume had the highest taurine production (Fig. 25). Because JJU concentrations were lower, two times as much JJU supernatant volume compared to CoaBC supernatant volume was required to produce a significant amount of taurine.

In Vitro Test 2: Taurine Production of JJU in BD7G and CoaBC in BL21(DE3)

  Since JJU expression in BL21(DE3) strain was not prominent in the supernatant, we performed another in vitro test in which PT7-coaBC (BBa_K3771080) was transformed into the BL21(DE3) strain, while PT7-jju (BBa_K3771000) was transformed into the BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding[4]. SDS-PAGE results confirm JJU and CoaBC expression in all samples (Fig. 26).

Fig. 26. Confirmation of protein expression of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein and whole cell samples. M: Marker; Lane 1: whole cell of JJU in BD7G; Lane 2: soluble protein of JJU in BD7G (~43 kDa); Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45 kDa)
Fig. 27. Taurine production of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein samples.

  PT7-coaBC (BBa_K3771080) was transformed into the BL21(DE3) strain, while PT7-jju (BBa_K3771000) was transformed into the BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding[4]. SDS-PAGE results confirm JJU and CoaBC expression in all samples (Fig. 26).

  The whole cell and supernatant JJU and CoaBC samples are collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. In In Vitro Test 1, a greater volume of JJU sample was needed to produce the maximum amount of taurine. However, this time when PT7-jju was transformed into the BD7G strain, 1:1 ratio of JJU to CoaBC supernatant had the highest taurine production (Fig. 27). This suggests the activity level of JJU does not significantly differ from that of CoaBC, and both are equally crucial and effective in converting L-cysteine to taurine.

In Vivo Tests for Taurine Production by CS-CSAD-CDO1

Achievements

1. In Vivo Test 1: Selected the medium in which taurine production is greatest for the CDO1 (BBa_K3771004), CSAD (BBa_K3771003), and CS (BBa_K3771002) enzymes[5]

2. In Vivo Test 2: Determined extracellular taurine concentrations in ∆tauD, ∆tauD-∆ompA double knockout (DkO), and TOP10 strains

3. In Vivo Test 3: Determined intracellular taurine concentrations in DkO and TOP10 strains

4. In Vivo Test 4: Determined taurine production yield under the regulation of the oxidative stress sensing system

Results

In Vivo Test 1: Choosing a Growth Medium

  Since the intestine is not as nutrient-rich as LB (lysogeny broth), we chose to test taurine production in both LB and M9 (minimal salts) mediums. M9 consists of fewer nutrients than LB and more closely mimics the nutrient composition of the human intestine.

  First, Ptrc-cdo1 (BBa_K3771075), PlacI-csad (BBa_K3771076), and Ptrc-cs (BBa_K3771078) were transformed into DH5α strain. In another sample, only Ptrc-cdo1 and Ptrc-csad (BBa_K3771077) were transformed. The two samples were each grown in LB with IPTG inducer (LB+), M9 with IPTG inducer (M9+) , and M9 without IPTG inducer (M9-) mediums.

  The samples’ respective growth curves are shown in Fig. 28 and 29. Interestingly, the sample with all three enzymes (Ptrc-cdo1 +PlacI-csad +Ptrc-cs) had a lower growth rate in M9+ medium than in M9- medium. In the sample with two enzymes (Ptrc-cdo1+Ptrc-csad), M9 medium with or without an inducer added produced similar growth curves. Both samples grew best in LB (Fig. 28, 29).

Fig. 28. Growth curve of Ptrc-cdo1 +PlacI-csad +Ptrc-cs in different growth mediums.
Fig. 29. Growth curve of Ptrc-cdo1+Ptrc-csad in different growth mediums.

  Taurine concentrations were highest at 12 hours when grown in LB (Fig. 30, 31). However, at 24 hours, taurine levels in all three mediums were very low. To more easily detect and quantify taurine production, we decided to use LB medium for the rest of the in vivo taurine production experiments. In addition, because there is no difference in taurine produced with or without CS, we decided to conduct the rest of the experiments with CSAD and CDO1 enzymes. In the future, we hope to perform more experiments with the CS enzyme.

Fig. 30. Taurine production of Ptrc-cdo1 +PlacI-csad +Ptrc-cs in different growth mediums.
Fig. 31. Taurine production of Ptrc-cdo1+Ptrc-csad in different growth mediums.
In Vivo Test 2: Determining Extracellular Taurine Concentrations in Different E. coli Strains

  Once the taurine production enzymes are expressed, they can be found intracellularly and extracellularly, resulting in different taurine concentrations inside and outside the bacteria. To determine extracellular taurine, the supernatants of the bacteria culture samples are collected, and taurine production was compared between different knockout strains.

  For sample preparation, Ptrc-cdo1 (BBa_K3771075) and Ptrc-csad (BBa_K3771077) are each transformed into ∆tauD (taurine dioxygenase gene deletion), ∆tauD-∆ompA (tauD and ompA gene deletion) double knockout (DkO), and TOP10 strains. In the ∆tauD strain, the deletion of the taurine dioxygenase gene prevents taurine from degradation by catabolic enzymes in the cell. In addition to the tauD gene deletion, the ompA gene is also knocked out in the ∆tauD-∆ompA double knockout strain, which prevents OmpA from interfering with IFN-γ binding to chimeric OmpA/OprF for the IFN-γ sensing system. TOP10 strain contains no gene deletions and serves as the control. More information about how the tauD and ompA genes were knocked out can be found in the Engineering page.

Fig. 32. Growth curve of Ptrc-cdo1+Ptrc-csad in different strains.

  For ∆tauD and DkO strains, OD600 of samples with no transformed plasmid were also recorded, serving as the negative control group (Fig. 33, 34). Even with a transformed plasmid, the bacteria still show adequate growth.

Fig. 33. Growth curve of Ptrc-cdo1+Ptrc-csad in ∆tauD.
Fig. 34. Growth curve of Ptrc-cdo1+Ptrc-csad in DkO.

  Extracellular CSAD and CDO1 expression at 8 and 10 hours after incubation were confirmed by SDS-PAGE (Fig. 35, 36).

Fig. 35. Confirmation of protein expression of CDO1 and CSAD in ∆tauD, DkO, and top10 at 8 hours. M: Marker; Lane 1: pSUI-Ptrc-cdo1 and pSUI-Ptrc-csad transformed into ∆tauD; Lane 2: pSUI-Ptrc-cdo1 and pSUI-Ptrc-csad transformed into DkO; Lane 3: pSUI-Ptrc-cdo1 and pSUI-Ptrc-csad transformed into top10
Fig. 36. Confirmation of protein expression of CDO1 and CSAD in ∆tauD and DkO at 10 hours.

  Taurine was successfully produced in ∆tauD, DKO, and TOP10 strains (Fig. 37) Taurine concentration is highest at 10 hours after incubation for both the ∆tauD and DKO strains (Fig. 38, 39). After confirming extracellular taurine concentrations by the DkO strain, we continued the following in vivo tests with the DkO strain.

Fig. 37. Taurine production (extracellular) of CDO1 and CSAD in different strains.
Fig. 38. Taurine production (extracellular) of CDO1 and CSAD in ∆tauD.
Fig. 39. Taurine production (extracellular) of CDO1 and CSAD in DkO.
In Vivo Test 3: Determining Intracellular Taurine Concentration in the DKO Strain

  To further understand the bacteria’s taurine production, we conducted another in vivo experiment to determine intracellular taurine concentration in the DkO and TOP10 strains. Instead of measuring taurine concentrations in the supernatants of the samples as we did for extracellular concentrations, intracellular taurine concentrations were determined by conducting HPLC on lysed bacterial pellets of each sample.

  For sample preparation, Ptrc-cdo1 (BBa_K3771075) and Ptrc-csad (BBa_K3771077) are each transformed into the DKO strain and TOP10 strain. Growth curves in each of the strains are shown in Fig. 40.

Fig. 40. Growth curves of Ptrc-cdo1+Ptrc-csad in DkO and top10.

  Expression of CSAD and CDO1 in both supernatant and whole cell samples was confirmed by SDS-PAGE (Fig. 41).

Fig. 41. Confirmation of protein expression of CDO1 and CSAD in DkO and TOP10.
Fig. 42. Taurine production (intracellular and extracellular) of CDO1 and CSAD in DkO and TOP10.

  To determine intracellular taurine concentration, HPLC was conducted on the whole cell samples, which contain all soluble proteins within the bacteria. Although CSAD expression is higher in the supernatant sample of the TOP10 strain than in the DKO strain according to SDS-PAGE results (Fig. 41), DKO strain still produced more taurine than the TOP10 strain (Fig. 42). This proves that the deletion of the tauD gene is crucial in increasing taurine concentrations.

In Vivo Test 4: Taurine Production Under the Regulation of the Oxidative Stress Sensing System

  From the previous in vivo tests, we proved that the DKO strain with our transformed plasmids can successfully express CDO1 and CSAD and produce taurine. In the final in vivo test, the trc promoter in Ptrc-csad was changed to the soxS promoter to determine extracellular taurine production under the regulation of the oxidative stress sensing system.

  For sample preparation, Ptrc-cdo1 (BBa_K3771077) and soxR-PsoxS-csad of the oxidative stress sensing system were both transformed into the DKO strain. Since IPTG is not naturally found in the human body, lactose was also added as an inducer instead of IPTG to consider taurine production in the intestine. Paraquat was added to induce the oxidative stress system. The growth curve is shown in Fig. 43 below.

Fig. 43. Growth curve of Ptrc-cdo1 + soxR-PsoxS-csad in DkO.

  CSAD and CDO1 expression after 8 hours of incubation was successful as shown in the SDS-PAGE results (Fig. 44).

Fig. 44. Confirmation of protein expression of CDO1 and CSAD with expression of CSAD regulated by soxS promoter in DkO.
Fig. 45. Taurine production (extracellular) of CDO1 and CSAD with expression of CSAD regulated by soxS promoter in DkO.

  The oxidative stress sensing system successfully expressed CSAD which aided in the production of taurine. Although having a lower taurine concentration than the IPTG-induced sample, the lactose-induced sample proves that the oxidative sensing system also has the potential to activate the bacteria’s taurine production in the human intestine (Fig. 45).

  In conclusion, from the experiment data collected through four in vivo tests, we proved that our bacteria with the tauD gene deletion can successfully produce taurine when under oxidative stress. To increase E. coli’s specificity in detecting and responding to depressive symptoms, we hope to exchange the lactose-induced trc promoter with the biobrick of the IFN-γ sensing system for the regulation of CDO1 expression.

References

  1. Aurand TC, March JC. Development of a synthetic receptor protein for sensing inflammatory mediators interferon‐γ and tumor necrosis factor‐α. Biotechnology and Bioengineering. 2016;113(3):492-500. doi:10.1002/bit.25832
  2. BRENDA - Information on EC 4.4.1.10 - cysteine lyase. Brenda-enzymes.org. Published 2021. Accessed October 6, 2021. https://www.brenda-enzymes.org/enzyme.php?ecno=4.4.1.10
  3. Mendes V, Green SR, Evans JC, et al. Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site. Nature Communications. 2021;12(1). doi:10.1038/s41467-020-20224-x
  4. Yu T-H, Yi Y-C, Shih I-Tai, Ng I-Son. Enhanced 5-Aminolevulinic Acid Production by Co-expression of Codon-Optimized hemA Gene with Chaperone in Genetic Engineered Escherichia coli. Applied Biochemistry and Biotechnology. 2019;191(1):299-312. doi:10.1007/s12010-019-03178-9
  5. Sung Ok Han et. al. Creating a New Pathway in Corynebacterium glutamicum for the Production of Taurine as a Food Additive. J. Agric. Food Chem. 2018, 66, 13454−13463Sung Ok Han et. al. Creating a New Pathway in Corynebacterium glutamicum for the Production of Taurine as a Food Additive. J. Agric. Food Chem. 2018, 66, 13454−13463